<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2409245940
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VEMLIDY 25MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TENOFOVIR ALAFENAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        940.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Gilead Sciences International Ltd 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Vemlidy contains the active substance <em>tenofovir alafenamide</em>.&nbsp; This is an <em>antiviral medicine</em>, known as a <em>nucleotide reverse transcriptase inhibitor</em> (NtRTI).</p><p>&nbsp;</p><p>Vemlidy is used to <strong>treat chronic (long</strong><strong>‑</strong><strong>term) hepatitis&nbsp;B</strong> in adults and children 6years of age and older, who weigh at least 25&nbsp;kg.&nbsp; Hepatitis&nbsp;B is an infection affecting the liver, caused by the hepatitis&nbsp;B virus.&nbsp; In patients with hepatitis&nbsp;B, this medicine controls the infection by stopping the virus from multiplying.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Vemlidy</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic</strong> to tenofovir alafenamide or any of the other ingredients of this medicine (listed in section&nbsp;7).</p><p>&nbsp;</p><p><strong>&agrave;</strong> If this applies to you, <strong>do not take Vemlidy and tell your doctor immediately</strong>.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Take care not to pass on your hepatitis&nbsp;B to other people.</strong>&nbsp; You can still infect others when taking this medicine.&nbsp; This medicinedoes not reduce the risk of passing on hepatitis&nbsp;B to others through sexual contact or blood contamination.&nbsp; You must continue to take precautions to avoid this.&nbsp; Discuss with your doctor the precautions needed to avoid infecting others. &nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor if you have a history of liver disease.&nbsp; </strong>Patients with liver disease, who are treated for hepatitis&nbsp;B with antiviral medicines, have a higher risk of severe and potentially fatal liver complications. Your doctor may need to carry out blood tests to monitor your liver function.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor or pharmacist if you have had kidney disease or if tests have shown problems with your kidneys</strong><strong>, before or during treatment</strong><strong>.</strong> Before starting treatment and during treatment with Vemlidy, your doctor may order blood or urine tests to monitor how your kidneys work.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor if you also have hepatitis&nbsp;C or D.&nbsp; </strong>This medicine has not been tested on patients who have hepatitis&nbsp;C or D as well as hepatitis&nbsp;B.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor if you also have HIV</strong>.&nbsp; If you are not sure whether you have HIV, your doctor should offer you HIV&nbsp;testing before you start taking this medicine for hepatitis&nbsp;B.</p><p>&nbsp;</p><p><strong>&agrave;</strong> If any of these apply to you, <strong>talk to your doctor before taking Vemlidy.</strong></p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>&nbsp;</p><p><strong>Do not give this medicine to children who are under 6&nbsp;years old, or weighing less than 25&nbsp;kg</strong>.&nbsp; It has not been tested in children aged less than 6&nbsp;years old or weighing less than 25&nbsp;kg.</p><p><strong>&nbsp;</strong></p><p><strong>Bone problems.</strong> Loss of bone mass has been reported in some children who received Vemlidy. The effects on long-term bone health and future fracture risk in children are uncertain. Your doctor will monitor this possible risk. Tell your doctor if any bone pain or fractures occur.</p><p>&nbsp;</p><p><strong>Other medicines and Vemlidy</strong></p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken</strong><strong> </strong><strong>or might take </strong><strong>any othermedicine.</strong>&nbsp; Vemlidy may interact with other medicines.&nbsp; As a result, the amounts of Vemlidy or other medicines in your blood may change.&nbsp; This may stop your medicines from working properly, or may make any side effects worse.</p><p>&nbsp;</p><p><strong>Medicines used in treating hepatitis&nbsp;B infection</strong></p><p>You should not take this medicine with other medicines containing:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tenofovir alafenamide</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>tenofovir disoproxil </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>adefovir dipivoxil</strong></p><p>&nbsp;</p><p><strong>Other types of medicines</strong></p><p>Talk to your doctor if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antibiotics </strong>used to treat bacterial infections including tuberculosis, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifabutin, rifampicin or rifapentine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anti</strong><strong>viral medicines used to treat HIV</strong>, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir or cobicistat boosted darunavir, lopinavir or atazanavir</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anticonvulsants</strong> used to treat epilepsy, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine, oxcarbazepine, phenobarbital or phenytoin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>herbal remedies</strong> used to treat depression and anxiety, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St.&nbsp;John&rsquo;s wort (<em>Hypericum perforatum</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antifungal medicines</strong> used to treat fungal infections, containing:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ketoconazole or itraconazole</p><p>&nbsp;</p><p><strong>&agrave;</strong> <strong>Tell your doctor if you are taking these or any other medicines.</strong></p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>&nbsp;</p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell your doctor immediately if you become pregnant.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not </strong><strong>breast‑feed during treatment with Vemlidy.</strong> It is recommended that you do not breast‑feed to avoid passing tenofovir alafenamide or tenofovir to the baby through breast milk.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>&nbsp;</p><p>Vemlidy can cause dizziness. If you feel dizzy when taking Vemlidy, do not drive and do not use any tools or machines.</p><p>&nbsp;</p><p><strong>Vemlidy contains lactose</strong></p><p>&nbsp;</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&nbsp;</p><p><strong>Vemlidy contains sodium</strong></p><p><strong>&nbsp;</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take </strong><strong>this medicine</strong><strong> exactly as your doctor</strong><strong> </strong><strong>has told you.</strong> Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The recommended dose is <strong>one tablet once a day with food</strong>. It is best to take Vemlidy with food to get the right levels of active substance in your body. &nbsp;Treatment should continue for as long as your doctor tells you.&nbsp; Usually this is for at least 6 to 12&nbsp;months and may be for many years.</p><p>&nbsp;</p><p><strong>If you take more Vemlidy than you should</strong></p><p>&nbsp;</p><p>If you accidentally take more than the recommended dose of Vemlidy you may be at increased risk of experiencing possible side&nbsp;effects with this medicine (see section&nbsp;5, <em>Possible side&nbsp;effects</em>).</p><p>&nbsp;</p><p>Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.</p><p>&nbsp;</p><p><strong>If you forget to take Vemlidy</strong></p><p>&nbsp;</p><p>It is important not to miss a dose. If you do miss a dose, work out how long since you should have taken it.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If it is less than 18&nbsp;hours</strong> after you usually take Vemlidy, take it as soon as you can, and then take your next dose at its regular time.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If it is more than 18&nbsp;hours</strong> after you usually take Vemlidy, then do not take the missed dose.&nbsp; Wait and take the next dose at the regular time. <strong>Do not take a double dose</strong> to make up for a forgotten tablet.</p><p>&nbsp;</p><p><strong>If you are sick (vomit) less than 1&nbsp;hour after taking Vemlidy</strong>, take another tablet. You do not need to take another tablet if you are sick (vomit) more than 1&nbsp;hour after taking Vemlidy.</p><p>&nbsp;</p><p><strong>If you stop taking Vemlidy</strong></p><p><strong>&nbsp;</strong></p><p><strong>Do not stop taking Vemlidy without your doctor&rsquo;s advice.</strong>&nbsp; Stopping treatment with Vemlidy may cause your hepatitis&nbsp;B to get worse.&nbsp; In some patients with advanced liver disease or cirrhosis, this could be life‑threatening.&nbsp; If you stop takingthis medicine, you will need regular health checks and blood tests for several months to check your hepatitis&nbsp;B infection.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor</strong> before you stop taking this medicine for any reason, particularly if you are experiencing any side effects or you have another illness.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor immediately</strong> about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis&nbsp;B infection.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor</strong> before you restart taking Vemlidy tablets.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side&nbsp;effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Very common </strong></p><p><em>(may affect more than 1 in 10&nbsp;people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&nbsp;</p><p><strong>Common </strong></p><p><em>(may affect up to 1 in 10&nbsp;people)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick <em>(vomiting)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick <em>(nausea)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain <em>(arthralgia)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itchiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling bloated</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wind <em>(flatulence)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling tired</p><p>&nbsp;</p><p><strong>Uncommon </strong></p><p><em>(may affect up to 1 in 100 people)</em></p><p>Swelling of the face, lips, tongue or throat (<em>angioedema</em>)</p><p>Hives <em>(urticaria)</em></p><p>&nbsp;</p><p><em>Tests may also show:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of a liver enzyme (ALT) in the blood</p><p>&nbsp;</p><p><strong>&agrave;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these side&nbsp;effects get serious tell your doctor.</strong></p><p>&nbsp;</p><p>During HBV therapy there may be an increase in weight, fasting levels of blood lipids and/or glucose. Your doctor will test for these changes.</p><p>&nbsp;</p><p><strong>Reporting of side&nbsp;effects</strong></p><p>&nbsp;</p><p><strong>If you get any side&nbsp;effects, talk to your doctor, pharmacist or nurse.</strong>&nbsp; This includes any possible side&nbsp;effects not listed in this leaflet. &nbsp;You can also report side effects directly via the national reporting system.</p><p>&nbsp;</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the bottle and carton after {EXP}.&nbsp; The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in the original package in order to protect from moisture. Keep the bottle tightly closed. &nbsp;Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines <em>via</em> wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The active substance is</strong> <em>tenofovir alafenamide</em>. Each Vemlidy film‑coated tablet contains tenofovir alafenamide fumarate, equivalent to 25&nbsp;mg of tenofovir alafenamide.</p><p>&nbsp;</p><p><strong>The other ingredients are</strong></p><p><em>Tablet core:</em></p><p>Lactose&nbsp;monohydrate, microcrystalline&nbsp;cellulose (E460(i)), croscarmellose&nbsp;sodium (E468), magnesium&nbsp;stearate (E470b).</p><p>&nbsp;</p><p><em>Film‑coating:</em></p><p>Polyvinyl&nbsp;alcohol&nbsp;(E1203), titanium&nbsp;dioxide&nbsp;(E171), macrogol&nbsp;(E1521), talc&nbsp;(E553b), iron oxide&nbsp;yellow&nbsp;(E172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Vemlidy film coated tablets are yellow, round, printed (or marked) with “GSI” on one side of the tablet and “25” on the other side of the tablet.  It comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets).  The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.
	
The following pack size is available: outer cartons containing 1 bottle of 30 film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Gilead Sciences Ireland UC</p><p>IDA Business &amp; Technology Park</p><p>Carrigtohill</p><p>County Cork</p><p>Ireland</p><p>Tel: +353 (0) 21 483 5500</p><p>Fax: +353 (0) 21 483 5518</p><p>E mail: csafety@gilead.com</p><p><strong>Bulk Manufacturer and Packaging Site</strong></p><p>Patheon Inc.</p><p>2100 Syntex Court</p><p>Mississauga,</p><p>Ontario L5N 7K9,</p><p>Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2023
EUMAY23SANOV24
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي فيمليدي على المادة الفعالة تينوفوفير الافيناميد. وهو دواء مضاد للفيروسات، يُعرف باسم <em>مثبط المنتسخة العكسية النوكليوتيدات</em> (NtRTI).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم فيمليدي <strong>لمعالجة التهاب الكبد الفيروسي بي (الطويل الأمد)</strong> لدى الراشدين والأطفال ابتداءً من عمر 6 سنوات &nbsp;فما فوق &nbsp;الذين يزيد وزنهم عن 25 كجم. التهاب الكبد الفيروسي بي هو عدوى تصيب الكبد، يسببها فيروس التهاب الكبد بي. يعمل هذا الدواء لدى المرضى المصابين بالتهاب الكبد الفيروسي بي على السيطرة على الالتهاب من خلال إيقاف انتشار الفيروس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول فيمليدي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني</strong> من حساسية من تينوفوفير الافيناميد أو أي مكون آخر من مكونات هذا الدواء (الواردة في القسم 7).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&szlig; إذا كانت هذه الحالة تنطبق عليك<strong> </strong><strong>فلا تتناول فيمليدي وأبلغ طبيبك في الحال.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تعطِ دواء التهاب الكبد الفيروسي بي الخاص بك للآخرين لاستعماله.</strong> فلا تزال إمكانية نقلك العدوى للآخرين قائمة مع استعمال هذا الدواء. هذا الدواء لا يقلل من احتمالات نقل التهاب الكبد الفيروسي بي للآخرين عبر الاتصال الجنسي أو الدم الملوث. يجب أن تستمر في تناول الدواء وفقًا لوصف الطبيب لتفادي ذلك. ناقش مع طبيبك الوصفة الطبية التي تحتاج إليها لتجنب إصابة الآخرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك إذا كانت لديك سوابق للإصابة بمرض الكبد.</strong> فالمرضى المصابون بمرض الكبد، الذين يعالجون من التهاب الكبد الفيروسي بي باستخدام دواء مضاد للفيروسات، تكون لديهم مخاطر أكبر لاحتمال حدوث مضاعفات شديدة أو مميتة بالكبد. قد يحتاج طبيبك إلى إجراء بعض تحاليل الدم لمراقبة وظائف الكبد لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك أو الصيدلي إذا كنت تعاني من مرض الكلى أو إذا أظهرت التحاليل مشاكل بالكليتين</strong><strong>،</strong><strong> </strong><strong>قبل أو في أثناء العلاج.</strong> قبل بدء العلاج وخلال فترة العلاج باستخدام فيمليدي، يطلب الطبيب تحاليل دم وبول لمراقبة وظائف الكليتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك إذا كنت تعاني أيضًا من التهاب الكبد الفيروسي سي أو دي</strong>. لم يتم اختبار هذا الدواء على المرضى المصابين بالتهاب الكبد الفيروسي سي أو دي وكذلك التهاب الكبد الفيروسي بي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك إذا كان لديك أيضًا فيروس نقص المناعة البشرية.</strong> إذا كنت غير متأكد من إصابتك بفيروس نقص المناعة البشرية، يجب على طبيبك أن يعرض عليك إجراء اختبار فيروس نقص المناعة البشرية قبل البدء بتناول هذا الدواء لالتهاب الكبد الفيروسي بي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&szlig; إذا كانت تنطبق عليك أي من هذه الحالات، <strong>فتحدث إلى طبيبك قبل تناول فيمليدي.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تعطِ هذا الدواء للأطفال الذين تقل أعمارهم عن 6 سنوات أو يقل وزنهم عن 25 كجم.</strong> لم يتم اختباره على الأطفال الذين تقل أعمارهم عن 6 سنوات أو يقل وزنهم عن 25 كجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل العظام.</strong> تم الإبلاغ عن فقدان كتلة العظام لدى بعض الأطفال الذين تناولوا فيمليدي. إن التأثيرات على صحة العظام على المدى الطويل وخطر الإصابة بالكسور في المستقبل لدى الأطفال غير مؤكدة. سيقوم طبيبك بمراقبة هذه المخاطر المحتملة. أخبر طبيبك في حالة حدوث أي ألم أو كسور في العظام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong><strong>فيمليدي و الأدوية الأخرى</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تأخذ، أو أخذت مؤخرًا أو قد تأخذ أي دواء آخر</strong>. قد تتفاعل فيمليدي مع الأدوية الأخرى. ونتيجة لذلك، قد يتغير مقدار فيمليدي أو غيره من الأدوية الموجودة في دمك. وقد يؤدي ذلك التأثير على مفعول هذه الأدوية، أو يحدث أي آثار جانبية أسوأ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية المستخدمة لعلاج التهاب الكبد الفيروسي بي</strong></p><p dir="RTL">يجب عليك ألا تأخذ هذا الدواء مع الأدوية الأخرى التي تحتوي على:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تينوفوفير الافيناميد</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تينوفوفير ديسوبروكسيل</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>اديفوفير ديبيفوكسيل</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أنواع أخرى من الأدوية</strong></p><p dir="RTL">التحدث إلى طبيبك إذا كنت تتناول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المضادات الحيوية</strong> المستخدمة لعلاج الالتهابات البكتيرية بما في ذلك السل، والتي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفابوتين، أو ريفامبيسين، أو ريفابنتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية المضادة للفيروسات المستخدمة لعلاج فيروس نقص المناعة البشرية</strong>، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريتونافير أو دارونافير معزز بالكوبيسيستات، لوبينافير أو أتازانافير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مضادات الصرع</strong> المستخدمة لعلاج الصرع، مثل:</p><p dir="RTL">- كاربامازيبين، أو أوكسكاربازيبين، أو فينوباربيتال أو فينيتوين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>العلاجات العشبية</strong> المستخدمة لعلاج الاكتئاب والقلق، التي تحتوي على:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة القديس يوحنا (<em>هايبيريكم بيرفراتم</em>)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>الأدوية المضادة للفطريات </strong>المستخدمة لعلاج الالتهابات الفطرية، التي تحتوي على:</p><p dir="RTL">- كيتوكونازول أو إيتراكونازول</p><p dir="RTL">&nbsp;</p><p dir="RTL">&szlig; <strong>أخبر طبيبك إذا كنت تأخذ هذه الأدوية أو غيرها.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنتِ حاملاً أو ترضعين رضاعة طبيعية، أو تعتقدين أنكِ حاملٌ أو تخططين لإنجاب طفل، فاستشيري طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبلغي طبيبك فورًا في حال حدوث حمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا ترضعي رضاعة طبيعية أثناء العلاج باستخدام فيمليدي</strong>. من المستحسن عدم الرضاعة الطبيعية لتجنب وصول تينوفوفير الافيناميد أو التينوفوفير للطفل عن طريق لبن الرضاعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">فيمليدي يمكن أن يسبب الدوار. إذا شعرت بالدوار عند أخذ فيمليدي، فلا تحاول القيادة أو استخدام أي أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فيمليدي على اللاكتوز</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أخبرك طبيبك أنك لا تتحمل بعض أنواع السكريات، فتواصل مع طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فيمليدي على الصوديوم</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملجم) لكل قرص، أي أنه يُعد &quot;خاليًا من الصوديوم&quot; تقريبًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تناول هذا الدواء دائمًا كما وصف لك الطبيب تمامًا</strong>. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي<strong> قرص واحد يوميًا مع الطعام</strong>. من الأفضل تناول فيمليدي مع الطعام للحصول على المستويات الصحيحة من المادة الفعالة في جسمك. يجب أن يستمر العلاج للفترة التي يخبرك بها طبيبك. لا تقل عادةً عن 6 إلى 12 شهرًا ويمكن أن تكون لعدة سنوات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت فيمليدي أكثر مما يجب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت عن طريق الخطأ جرعة من فيمليدي أكثر من الموصى بها فقد يزيد ذلك من خطر تعرضك للآثار الجانبية المحتملة لهذا الدواء (راجع القسم 5، <em>الآثار الجانبية المحتملة</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتصل بطبيبك أو أقرب قسم طوارئ على الفور للمشورة. احتفظ بزجاجة الأقراص معك بحيث يمكنك بسهولة وصف ما تناولته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول فيمليدي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم عدم تفويت الجرعة. إذا نسيت أخذ جرعة، فاحسب الفترة التي مرت على موعد تناولها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت أقل من </strong>18<strong> ساعة</strong> بعد الموعد الذي تتناول فيه فيمليدي عادةً، فتناولها في أسرع وقت ممكن، ثم تناول الجرعة التي تليها في وقتها المعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كانت أكثر من </strong>18<strong> ساعة</strong> بعد الموعد الذي تتناول فيه فيمليدي عادةً، فلا تأخذ الجرعة التي فاتتك. انتظر وتناول الجرعة التالية في الوقت المعتاد. لا تأخذ جرعة مزدوجة لتعويض القرص الذي نسيت تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا عانيت من الغثيان (القيء) بعد أقل من </strong>1<strong> ساعة من تناول فيمليدي،</strong> فتناول قرصًا آخر. لا تحتاج إلى تناول قرصٍ آخر إذا عانيت من الغثيان (القيء) بعد أكثر من 1 ساعة من تناول فيمليدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول فيمليدي</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول فيمليدي دون استشارة الطبيب</strong>. إيقاف العلاج باستخدام فيمليدي قد يؤدي إلى تفاقم حالة التهاب الكبد الفيروسي بي لديك. لدى بعض المرضى الذين يعانون من مرض الكبد في مراحل متقدمة أو من تليف الكبد، قد يشكل ذلك تهديدًا لحياتهم. إذا توقفت عن تناول هذا الدواء، فسوف تحتاج إلى فحوصات طبية دورية وتحاليل دم على مدى عدة أشهر لتتعرف على وضع التهاب الكبد الفيروسي بي لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك</strong> قبل التوقف عن تناول هذا الدواء لأي سبب من الأسباب، خاصةً إذا كنت تعاني من أي آثار جانبية أو لديك مرض آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أبلغ طبيبك فورًا</strong> بأي أعراض جديدة أو غير عادية بعد التوقف عن العلاج، وخاصةً الأعراض المتعلقة بعدوى التهاب الكبد الفيروسي بي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تحدث إلى طبيبك</strong> قبل البدء في تناول أقراص فيمليدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى عن استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارًا جانبية، على الرغم من أنها لا تحدث للجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة جدًا</strong></p><p dir="RTL"><em>(قد تحدث لأكثر من شخص من بين كل </em><em>10</em><em> أشخاص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشائعة</strong></p><p dir="RTL"><em>(قد تحدث لشخص من بين كل </em><em>10</em><em> أشخاص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان <em>(القيء)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان <em>(الدوخة)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل <em>(ألم مفصلي)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالانتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الريح <em>(الغازات)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة</strong></p><p dir="RTL"><em>(قد تحدث لما يصل إلى شخص واحد من بين كل 100 شخص)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه أو الشفتين أو اللسان أو الحلق <em>(وذمة وعائية)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشرى <em>(أريتكاريا)</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>قد تظهر التحاليل أيضًا:</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم الكبد (ALT) في الدم</p><p dir="RTL">&nbsp;</p><p dir="RTL">&szlig;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا تفاقم أي من هذه الآثار الجانبية فأبلغ طبيبك.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">خلال علاج فيروس التهاب الكبد ب (HBV) قد تكون هناك زيادة في الوزن وارتفاع في مستويات الدهون في الدم و/أو السكر أثناء الصوم. ويجري طبيبك فحوصات للكشف عن هذه التغيرات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا عانيت من أي أعراض جانبية، فاستشر الطبيب أو الصيدلي أو الممرضة.</strong> يشمل ذلك أي أعراض جانبية محتملة ليست واردة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً عن طريق نظام الإبلاغ الوطني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بإبلاغك عن الآثار الجانبية فأنت تساعد في توفير مزيد من المعلومات عن سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيدًا عن نظر ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المبين على الزجاجة والعبوة الكرتونية بعد كلمة {EXP} (الانتهاء). يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في العبوة الأصلية للحماية من الرطوبة. أغلق الزجاجة بإحكام. لا يخزن في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء بإلقائه في مياه الصرف الصحي أو بالنفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. فهذه الإجراءات تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المادة الفعالة هي</strong> تينوفوفير الافيناميد. كل قرص مغلف من فيمليدي يحتوي على تينوفوفير الافيناميد فيوماريت، يساوي 25 ملجم من تينوفوفير الافيناميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المكونات الأخرى هي</strong></p><p dir="RTL"><em>لب القرص:</em></p><p dir="RTL">اللاكتوز أحادي الهيدرات، السليلوز دقيق التبلور )(E460(i)، كروسكارميلوسي الصوديوم (E468)، ستيرات المغنسيوم (E470b).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>التغليف:</em></p><p dir="RTL">بولي فينيل الكحول (E1203)، وثاني أكسيد التيتانيوم (E171)، ماكروغول (E1521)، تلك (E553b)، أكسيد الحديد الأصفر (E172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص فيمليدي المغلفة تكون صفراء اللون، ودائرية الشكل، مطبوعًا عليها (أو تحمل علامة) &quot;GSI&quot; على أحد أوجه القرص وعلى الوجه الآخر &quot;25&quot;. يأتي الدواء في زجاجة تحتوي على 30 قرصًا (تحتوي على مادة السيليكا الهلامية التي يجب أن تظل في الزجاجة للمساعدة في حماية الأقراص). تغلف مادة السيليكا الهلامية في كيس منفصل أو علبة صغيرة ويجب عدم بلعها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتوفر عبوات بالأحجام التالية: تحتوي العبوة الخارجية على 1 زجاجة بها 30 قرصًا مغلفًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب تصريح التسويق</strong> <strong>،</strong><strong>مصنع الكميات غير المعبأة </strong>&nbsp;<strong>،</strong><strong>موقع التعبئة وإنتاج الدفعة النهائية </strong></p><p dir="RTL">جيلياد للعلوم إيرلندا يو سي</p><p dir="RTL">حديقة آي دي أي للأعمال والتكنولوجيا</p><p dir="RTL">كاريغتوهيل</p><p dir="RTL">مقاطعة كورك</p><p dir="RTL">إيرلندا</p><p dir="RTL">الهاتف: +353 (0) 21 483 5500</p><p dir="RTL">الفاكس: +353 (0) 21 483 5518</p><p dir="RTL">البريد الإلكتروني: csafety@gilead.com</p><p dir="RTL"><strong>مصنع الكميات غير المعبأة </strong><strong>و</strong><strong>موقع التعبئة</strong><strong> </strong></p><p dir="RTL">شركة باثيون</p><p dir="RTL">2100 سينتكس كورت</p><p dir="RTL">ميسيسوجا،</p><p dir="RTL">أونتاريو L5N 7K9،</p><p dir="RTL">كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            2023/05
EUMAY23SANOV24
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Vemlidy® 25 mg film coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.
Excipient with known effect
Each tablet contains 95 mg lactose (as monohydrate).
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet.

Yellow, round, film coated tablets, 8 mm in diameter, debossed with “GSI” on one side of the tablet and “25” on the other side of the tablet.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vemlidy is indicated for the treatment of chronic hepatitis&nbsp;B in adults and &nbsp;paediatric patients 6&nbsp;years of age and older weighing at least 25&nbsp;kg) (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of CHB.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Adults and paediatric patients at least 6&nbsp;years of age and older weighing at least 25&nbsp;kg: one tablet once daily.</p><p>&nbsp;</p><p><em>Treatment discontinuation</em></p><p>Treatment discontinuation may be considered as follows (see section&nbsp;4.4):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In HBeAg‑positive patients without cirrhosis, treatment should be administered for at least 6‑12&nbsp;months after HBe&nbsp;seroconversion (HBeAg&nbsp;loss and HBV&nbsp;DNA&nbsp;loss with anti‑HBe&nbsp;detection) is confirmed or until HBs&nbsp;seroconversion or until there is loss of efficacy (see section&nbsp;4.4). Regular reassessment is recommended after treatment discontinuation to detect virological relapse.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In HBeAg‑negative patients without cirrhosis, treatment should be administered at least until HBs&nbsp;seroconversion or until there is evidence of loss of efficacy. With prolonged treatment for more than 2&nbsp;years, regular reassessment is recommended to confirm that continuing the selected therapy remains appropriate for the patient.</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>If a dose is missed and less than 18&nbsp;hours have passed from the time it is usually taken, the patient should take this medicinal product as soon as possible and then resume their normal dosing schedule.&nbsp; If more than 18&nbsp;hours have passed from the time it is usually taken, the patient should not take the missed dose and should simply resume the normal dosing schedule.</p><p>&nbsp;</p><p>If the patient vomits within 1&nbsp;hour of taking the treatment, the patient should take another tablet.&nbsp; If the patient vomits more than 1&nbsp;hour after taking the treatment, the patient does not need to take another tablet.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dose adjustment of this medicinal product is required in patients aged 65&nbsp;years and older (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dose adjustment of this medicinal product is required in adults or adolescents (aged at least 12&nbsp;years and of at least 35&nbsp;kg body weight) with estimated creatinine clearance (CrCl)&nbsp;&ge;&nbsp;15&nbsp;mL/min or in patients with CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min who are receiving haemodialysis.</p><p>&nbsp;</p><p>On days of haemodialysis, this medicinal product should be administered after completion of haemodialysis treatment (see section&nbsp;5.2).</p><p>&nbsp;</p><p>No dosing recommendations can be given for patients with CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min who are not receiving haemodialysis (see section&nbsp;4.4).</p><p>&nbsp;</p><p>No data are available to make dose recommendations in children aged less than 12 years and of less than 35 kg body weight with renal impairment.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of this medicinal product is required in patients with hepatic impairment (see sections&nbsp;4.4 and&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Vemlidy in children younger than 6&nbsp;years of age or weighing &lt;&nbsp;25&nbsp;kg, have not yet been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>Oral use.&nbsp; Vemlidy film‑coated tablets should be taken with food (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatitis B Virus (HBV)&nbsp;transmission</u></p><p>&nbsp;</p><p>Patients must be advised that this medicinal product does not prevent the risk of transmission of HBV to others through sexual contact or contamination with blood. Appropriate precautions must continue to be used.</p><p>&nbsp;</p><p><u>Patients with decompensated liver disease</u></p><p>&nbsp;</p><p>There are limited data on the safety and efficacy of tenofovir alafenamide in HBV&nbsp;infected patients with decompensated liver disease and who have a Child Pugh Turcotte (CPT) score &gt;&nbsp;9 (i.e. class&nbsp;C). These patients may be at higher risk of experiencing serious hepatic or renal adverse reactions. Therefore, hepatobiliary and renal parameters should be closely monitored in this patient population (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Exacerbation of hepatitis</u></p><p>&nbsp;</p><p><em>Flares on treatment </em></p><p>Spontaneous exacerbations in CHB are relatively common and are characterised by transient increases in serum&nbsp;alanine aminotransferase (ALT). After initiating antiviral therapy, serum&nbsp;ALT may increase in some patients. &nbsp;In patients with compensated liver disease, these increases in serum&nbsp;ALT are generally not accompanied by an increase in serum bilirubin concentrations or hepatic decompensation. Patients with cirrhosis may be at a higher risk for hepatic decompensation following hepatitis exacerbation, and therefore should be monitored closely during therapy.</p><p>&nbsp;</p><p><em>Flares after treatment discontinuation</em></p><p>Acute exacerbation of hepatitis has been reported in patients who have discontinued treatment for CHB, usually in association with rising HBV&nbsp;DNA levels in plasma. The majority of cases are self‑limited but severe exacerbations, including fatal outcomes, may occur after discontinuation of treatment for CHB. &nbsp;Hepatic function should be monitored at repeated intervals with both clinical and laboratory follow‑up for at least 6&nbsp;months after discontinuation of treatment for CHB. If appropriate, resumption of CHB therapy may be warranted.</p><p>&nbsp;</p><p>In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post‑treatment exacerbation of hepatitis may lead to hepatic decompensation. Liver flares are especially serious, and sometimes fatal in patients with decompensated liver disease.</p><p><u>&nbsp;</u></p><p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p><em>Patients with creatinine clearance &lt;&nbsp;30&nbsp;mL/min</em></p><p>The use of tenofovir alafenamide once daily in patients with CrCl&nbsp;&ge;&nbsp;15&nbsp;mL/min and &lt;&nbsp;30&nbsp;mL/min is based on Week&nbsp;96 data on the efficacy and safety of switching from another antiviral regimen to tenofovir alafenamide in an open‑label clinical study of virologically suppressed HBV-infected patients (see sections&nbsp;4.8 and 5.1). There are very limited data on the safety and efficacy of tenofovir alafenamide in HBV-infected patients with CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min on chronic haemodialysis (see sections&nbsp;4.8, 5.1 and 5.2).</p><p>&nbsp;</p><p>The use of this medicinal product is not recommended in patients with CrCl&nbsp;&lt;&nbsp;15&nbsp;mL/min who are not receiving haemodialysis (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><u>Nephrotoxicity</u></p><p>&nbsp;</p><p>A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section&nbsp;5.3).</p><p><u>&nbsp;</u></p><p>It is recommended that renal function is assessed in all patients prior to, or when initiating, therapy with this treatment and that it is also monitored during therapy in all patients as clinically appropriate. In patients who develop clinically significant decreases in renal function, or evidence of proximal renal tubulopathy, discontinuation of this medicinal product should be considered.</p><p><u>&nbsp;</u></p><p><u>Patients co‑infected with HBV and hepatitis&nbsp;C or D virus</u></p><p>&nbsp;</p><p>There are no data on the safety and efficacy of tenofovir alafenamide in patients co‑infected with hepatitis&nbsp;C (HCV) or D (HDV) virus. Co‑administration guidance for the treatment of HCV should be followed (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>HBV and Human Immunodeficiency Virus (HIV) co‑infection</u></p><p>&nbsp;</p><p>HIV&nbsp;antibody testing should be offered to all HBV&nbsp;infected patients whose HIV‑1 infection status is unknown before initiating therapy with this medicinal product.&nbsp; In patients who are co‑infected with HBV and HIV, Vemlidy should be co‑administered with other antiretroviral medicinal products to ensure that the patient receives an appropriate regimen for treatment of HIV (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Co‑administration with other medicinal products</u></p><p>&nbsp;</p><p>This medicinal product should not be co‑administered with medicinal products containing tenofovir alafenamide, tenofovir disoproxil or adefovir dipivoxil.</p><p>&nbsp;</p><p>Co‑administration of this treatment with certain anticonvulsants (e.g.&nbsp;carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g.&nbsp;rifampicin, rifabutin and rifapentine) or St.&nbsp;John&rsquo;s&nbsp;wort, all of which are inducers of P‑glycoprotein (P‑gp) and may decrease tenofovir alafenamide plasma concentrations, is not recommended.</p><p>&nbsp;</p><p>Co‑administration of this treatment with strong inhibitors of P‑gp (e.g. itraconazole and ketoconazole) may increase tenofovir alafenamide plasma concentrations. &nbsp;Co‑administration is not recommended.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Reductions in bone mineral density (BMD &ge;&nbsp;4%) of the lumbar spine and of whole body have been reported in some paediatric patients 6 years of age and older weighing at least 25&nbsp;kg who received tenofovir alafenamide for 48 weeks (see sections 4.8 and 5.1). The long-term effects of changes in BMD on the growing bone, including the risk of fracture, are uncertain. A multidisciplinary approach is recommended to decide the appropriate monitoring during treatment.</p><p>&nbsp;</p><p><u>Excipients with known effect</u></p><p>&nbsp;</p><p>This medicinal product contains lactose monohydrate.&nbsp; Patients with rare hereditary problems of galactose intolerance, total&nbsp;lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium‑free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p>&nbsp;</p><p>This medicinal product should not be co‑administered with medicinal products containing tenofovir disoproxil, tenofovir alafenamide or adefovir dipivoxil.</p><p>&nbsp;</p><p><u>Medicinal products that may affect tenofovir alafenamide</u></p><p>&nbsp;</p><p>Tenofovir alafenamide is transported by P‑gp and breast cancer resistance protein (BCRP). Medicinal products that are P‑gp inducers (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital or St.&nbsp;John&rsquo;s&nbsp;wort) are expected to decrease plasma concentrations of tenofovir alafenamide, which may lead to loss of therapeutic effect of Vemlidy. Co‑administration of such medicinal products with tenofovir alafenamide is not recommended.</p><p>&nbsp;</p><p>Co‑administration of tenofovir alafenamide with medicinal products that inhibit P‑gp and BCRP may increase plasma concentrations of tenofovir alafenamide. Co‑administration of strong inhibitors of P‑gp with tenofovir alafenamide is not recommended.</p><p>&nbsp;</p><p>Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 <em>in&nbsp;vitro</em>. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and/or OATP1B3.</p><p>&nbsp;</p><p><u>Effect of tenofovir alafenamide on other medicinal products</u></p><p>&nbsp;</p><p>Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 <em>in&nbsp;vitro</em>. It is not an inhibitor or inducer of CYP3A <em>in&nbsp;vivo</em>.</p><p>&nbsp;</p><p>Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT)&nbsp;1A1 <em>in&nbsp;vitro</em>. It is not known whether tenofovir alafenamide is an inhibitor of other UGT&nbsp;enzymes.</p><p>&nbsp;</p><p>Drug interaction information for Vemlidy with potential concomitant medicinal products is summarised in Table&nbsp;1 below (increase is indicated as &ldquo;&uarr;&rdquo;, decrease as &ldquo;&darr;&rdquo;, no change as &ldquo;&harr;&rdquo;; twice daily as &ldquo;b.i.d.&rdquo;, single&nbsp;dose as &ldquo;s.d.&rdquo;, once daily as &ldquo;q.d.&rdquo;).&nbsp; The drug interactions described are based on studies conducted with tenofovir alafenamide, or are potential drug interactions that may occur with Vemlidy.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Interactions Between Vemlidy and Other Medicinal Products</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><thead><tr><td style="vertical-align:top"><p><strong>Medicinal product by therapeutic areas</strong></p></td><td style="vertical-align:top"><p><strong>Effects on drug levels.<sup>a,b</sup></strong></p><p><strong>Mean ratio (90% confidence interval) for AUC, C<sub>max</sub>, C<sub>min</sub></strong></p></td><td style="vertical-align:top"><p><strong>Recommendation concerning co‑administration with Vemlidy</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTICONVULSANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Carbamazepine</p><p>(300&nbsp;mg orally, b.i.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(25&nbsp;mg orally, s.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&darr; C<sub>max</sub> 0.43 (0.36, 0.51)</p><p>&darr; AUC 0.45 (0.40, 0.51)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&darr; C<sub>max</sub> 0.70 (0.65, 0.74)</p><p>&harr; AUC 0.77 (0.74, 0.81)</p></td><td style="vertical-align:top"><p>Co-administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Oxcarbazepine</p><p>Phenobarbital</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co-administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Phenytoin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co-administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Midazolam<sup>d</sup></p><p>(2.5&nbsp;mg orally, s.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Midazolam</em></p><p>&harr; C<sub>max</sub> 1.02 (0.92, 1.13)</p><p>&harr; AUC 1.13 (1.04, 1.23)</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment of midazolam (administered orally or intravenously) is required.</p></td></tr><tr><td style="vertical-align:top"><p>Midazolam<sup>d</sup></p><p>(1&nbsp;mg&nbsp;intravenously, s.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Midazolam</em></p><p>&harr; C<sub>max</sub> 0.99 (0.89, 1.11)</p><p>&harr; AUC 1.08 (1.04, 1.14)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIDEPRESSANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Sertraline</p><p>(50&nbsp;mg orally, s.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>e</sup></p><p>(10&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&harr; C<sub>max</sub> 1.00 (0.86, 1.16)</p><p>&harr; AUC 0.96 (0.89, 1.03)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&harr; C<sub>max</sub> 1.10 (1.00, 1.21)</p><p>&harr; AUC 1.02 (1.00, 1.04)</p><p>&harr; C<sub>min</sub> 1.01 (0.99, 1.03)</p></td><td rowspan="2" style="vertical-align:top"><p>No dose adjustment of Vemlidy or sertraline is required.</p></td></tr><tr><td style="vertical-align:top"><p>Sertraline</p><p>(50&nbsp;mg orally, s.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>e</sup></p><p>(10&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Sertraline</em></p><p>&harr; C<sub>max</sub> 1.14 (0.94, 1.38)</p><p>&harr; AUC 0.93 (0.77, 1.13)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIFUNGALS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole</p><p>Ketoconazole</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&uarr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIMYCOBACTERIALS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin</p><p>Rifapentine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co-administration is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HCV ANTIVIRAL AGENTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir (400 mg orally, q.d.)</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&harr; Sofosbuvir</p><p>&harr; GS‑331007</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or sofosbuvir is required.</p></td></tr><tr><td style="vertical-align:top"><p>Ledipasvir/sofosbuvir</p><p>(90&nbsp;mg/400&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>f</sup></p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Ledipasvir</em></p><p>&harr; C<sub>max</sub> 1.01 (0.97, 1.05)</p><p>&harr; AUC 1.02 (0.97, 1.06)</p><p>&harr; C<sub>min</sub> 1.02 (0.98, 1.07)</p><p>&nbsp;</p><p><em>Sofosbuvir</em></p><p>&harr; C<sub>max</sub> 0.96 (0.89, 1.04)</p><p>&harr; AUC 1.05 (1.01, 1.09)</p><p>&nbsp;</p><p><em>GS‑331007<sup>g</sup></em></p><p>&harr; C<sub>max</sub> 1.08 (1.05, 1.11)</p><p>&harr; AUC 1.08 (1.06, 1.10)</p><p>&harr; C<sub>min</sub> 1.10 (1.07, 1.12)</p><p>&nbsp;</p><p><em>Tenofovir alafenamide</em></p><p>&harr; C<sub>max</sub> 1.03 (0.94, 1.14)</p><p>&harr; AUC 1.32 (1.25, 1.40)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&uarr; C<sub>max</sub> 1.62 (1.56, 1.68)</p><p>&uarr; AUC 1.75 (1.69, 1.81)</p><p>&uarr; C<sub>min</sub> 1.85 (1.78, 1.92)</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or ledipasvir/sofosbuvir is required.</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir</p><p>(400&nbsp;mg/100&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&harr; Sofosbuvir</p><p>&harr; GS‑331007</p><p>&harr; Velpatasvir</p><p>&uarr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or sofosbuvir/velpatasvir is required.</p></td></tr><tr><td style="vertical-align:top"><p>Sofosbuvir/velpatasvir/ voxilaprevir (400&nbsp;mg/100&nbsp;mg/ 100&nbsp;mg&nbsp;+&nbsp;100&nbsp;mg<sup>i</sup> orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>f</sup></p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Sofosbuvir</em></p><p>&harr; C<sub>max</sub> 0.95 (0.86, 1.05)</p><p>&harr; AUC 1.01 (0.97, 1.06)</p><p>&nbsp;</p><p><em>GS‑331007<sup>g</sup></em></p><p>&harr; C<sub>max</sub> 1.02 (0.98, 1.06)</p><p>&harr; AUC 1.04 (1.01, 1.06)</p><p>&nbsp;</p><p><em>Velpatasvir</em></p><p>&harr; C<sub>max</sub> 1.05 (0.96, 1.16)</p><p>&harr; AUC 1.01 (0.94, 1.07)</p><p>&harr; C<sub>min</sub> 1.01 (0.95, 1.09)</p><p>&nbsp;</p><p><em>Voxilaprevir</em></p><p>&harr; C<sub>max</sub> 0.96 (0.84, 1.11)</p><p>&harr; AUC 0.94 (0.84, 1.05)</p><p>&harr; C<sub>min</sub> 1.02 (0.92, 1.12)</p><p>&nbsp;</p><p><em>Tenofovir alafenamide</em></p><p>&uarr; C<sub>max</sub> 1.32 (1.17, 1.48)</p><p>&uarr; AUC 1.52 (1.43, 1.61)</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or sofosbuvir/velpatasvir/voxilaprevir is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HIV ANTIRETROVIRAL AGENTS &ndash; PROTEASE INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/cobicistat</p><p>(300&nbsp;mg/150&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(10&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&uarr; C<sub>max</sub> 1.80 (1.48, 2.18)</p><p>&uarr; AUC 1.75 (1.55, 1.98)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&uarr; C<sub>max</sub> 3.16 (3.00, 3.33)</p><p>&uarr; AUC 3.47 (3.29, 3.67)</p><p>&uarr; C<sub>min</sub> 3.73 (3.54, 3.93)</p><p>&nbsp;</p><p><em>Atazanavir</em></p><p>&harr; C<sub>max</sub> 0.98 (0.94, 1.02)</p><p>&harr; AUC 1.06 (1.01, 1.11)</p><p>&harr; C<sub>min</sub> 1.18 (1.06, 1.31)</p><p>&nbsp;</p><p><em>Cobicistat</em></p><p>&harr; C<sub>max</sub> 0.96 (0.92, 1.00)</p><p>&harr; AUC 1.05 (1.00, 1.09)</p><p>&uarr; C<sub>min</sub> 1.35 (1.21, 1.51)</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir</p><p>(300&nbsp;mg/100&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(10&nbsp;mg orally, s.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&uarr; C<sub>max</sub> 1.77 (1.28, 2.44)</p><p>&uarr; AUC 1.91 (1.55, 2.35)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&uarr; C<sub>max</sub> 2.12 (1.86, 2.43)</p><p>&uarr; AUC 2.62 (2.14, 3.20)</p><p>&nbsp;</p><p><em>Atazanavir</em></p><p>&harr; C<sub>max</sub> 0.98 (0.89, 1.07)</p><p>&harr; AUC 0.99 (0.96, 1.01)</p><p>&harr; C<sub>min</sub> 1.00 (0.96, 1.04)</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/cobicistat</p><p>(800&nbsp;mg/150&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&harr; C<sub>max</sub> 0.93 (0.72, 1.21)</p><p>&harr; AUC 0.98 (0.80, 1.19)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&uarr; C<sub>max</sub> 3.16 (3.00, 3.33)</p><p>&uarr; AUC 3.24 (3.02, 3.47)</p><p>&uarr; C<sub>min</sub> 3.21 (2.90, 3.54)</p><p>&nbsp;</p><p><em>Darunavir</em></p><p>&harr; C<sub>max</sub> 1.02 (0.96, 1.09)</p><p>&harr; AUC 0.99 (0.92, 1.07)</p><p>&harr; C<sub>min</sub> 0.97 (0.82, 1.15)</p><p>&nbsp;</p><p><em>Cobicistat</em></p><p>&harr; C<sub>max</sub> 1.06 (1.00, 1.12)</p><p>&harr; AUC 1.09 (1.03, 1.15)</p><p>&harr; C<sub>min</sub> 1.11 (0.98, 1.25)</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir</p><p>(800&nbsp;mg/100&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(10&nbsp;mg orally, s.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&uarr; C<sub>max</sub> 1.42 (0.96, 2.09)</p><p>&harr; AUC 1.06 (0.84, 1.35)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&uarr; C<sub>max</sub> 2.42 (1.98, 2.95)</p><p>&uarr; AUC 2.05 (1.54, 2.72)</p><p>&nbsp;</p><p><em>Darunavir</em></p><p>&harr; C<sub>max</sub> 0.99 (0.91, 1.08)</p><p>&harr; AUC 1.01 (0.96, 1.06)</p><p>&harr; C<sub>min</sub> 1.13 (0.95, 1.34)</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir</p><p>(800&nbsp;mg/200&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(10&nbsp;mg orally, s.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&uarr; C<sub>max</sub> 2.19 (1.72, 2.79)</p><p>&uarr; AUC 1.47 (1.17, 1.85)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&uarr; C<sub>max</sub> 3.75 (3.19, 4.39)</p><p>&uarr; AUC 4.16 (3.50, 4.96)</p><p>&nbsp;</p><p><em>Lopinavir</em></p><p>&harr; C<sub>max</sub> 1.00 (0.95, 1.06)</p><p>&harr; AUC 1.00 (0.92, 1.09)</p><p>&harr; C<sub>min</sub> 0.98 (0.85, 1.12)</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir/ritonavir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HIV ANTIRETROVIRAL AGENTS &ndash; INTEGRASE INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Dolutegravir</p><p>(50&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(10&nbsp;mg orally, s.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&uarr; C<sub>max</sub> 1.24 (0.88, 1.74)</p><p>&uarr; AUC 1.19 (0.96, 1.48)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&harr; C<sub>max</sub> 1.10 (0.96, 1.25)</p><p>&uarr; AUC 1.25 (1.06, 1.47)</p><p>&nbsp;</p><p><em>Dolutegravir</em></p><p>&harr; C<sub>max</sub> 1.15 (1.04, 1.27)</p><p>&harr; AUC 1.02 (0.97, 1.08)</p><p>&harr; C<sub>min</sub> 1.05 (0.97, 1.13)</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or dolutegravir is required.</p></td></tr><tr><td style="vertical-align:top"><p>Raltegravir</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&harr; Tenofovir alafenamide</p><p>&harr; Raltegravir</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or raltegravir is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HIV ANTIRETROVIRAL AGENTS &ndash; NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz</p><p>(600&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>h</sup></p><p>(40&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&darr; C<sub>max</sub> 0.78 (0.58, 1.05)</p><p>&harr; AUC 0.86 (0.72, 1.02)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&darr; C<sub>max</sub> 0.75 (0.67, 0.86)</p><p>&harr; AUC 0.80 (0.73, 0.87)</p><p>&harr; C<sub>min</sub> 0.82 (0.75, 0.89)</p><p>&nbsp;</p><p><em>Expected:</em></p><p>&harr; Efavirenz</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or efavirenz is required.</p></td></tr><tr><td style="vertical-align:top"><p>Nevirapine</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&harr; Tenofovir alafenamide</p><p>&harr; Nevirapine</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or nevirapine is required.</p></td></tr><tr><td style="vertical-align:top"><p>Rilpivirine</p><p>(25&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide</p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Tenofovir alafenamide</em></p><p>&harr; C<sub>max</sub> 1.01 (0.84, 1.22)</p><p>&harr; AUC 1.01 (0.94, 1.09)</p><p>&nbsp;</p><p><em>Tenofovir</em></p><p>&harr; C<sub>max</sub> 1.13 (1.02, 1.23)</p><p>&harr; AUC 1.11 (1.07, 1.14)</p><p>&harr; C<sub>min</sub> 1.18 (1.13, 1.23)</p><p>&nbsp;</p><p><em>Rilpivirine</em></p><p>&harr; C<sub>max</sub> 0.93 (0.87, 0.99)</p><p>&harr; AUC 1.01 (0.96, 1.06)</p><p>&harr; C<sub>min</sub> 1.13 (1.04, 1.23)</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or rilpivirine is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HIV ANTIRETROVIRAL AGENTS &ndash; CCR5&nbsp;RECEPTOR ANTAGONIST</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Maraviroc</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&harr; Tenofovir alafenamide</p><p>&harr; Maraviroc</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or maraviroc is required.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>HERBAL SUPPLEMENTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>St.&nbsp;John&rsquo;s&nbsp;wort <em>(Hypericum perforatum)</em></p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p><em>Expected:</em></p><p>&darr; Tenofovir alafenamide</p></td><td style="vertical-align:top"><p>Co‑administration is not recommended.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ORAL CONTRACEPTIVES</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Norgestimate</p><p>(0.180&nbsp;mg/0.215&nbsp;mg/ 0.250&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Ethinylestradiol</p><p>(0.025&nbsp;mg orally, q.d.)</p><p>&nbsp;</p><p>Tenofovir alafenamide<sup>c</sup></p><p>(25&nbsp;mg orally, q.d.)</p></td><td style="vertical-align:top"><p><em>Norelgestromin</em></p><p>&harr; C<sub>max</sub> 1.17 (1.07, 1.26)</p><p>&harr; AUC 1.12 (1.07, 1.17)</p><p>&harr; C<sub>min</sub> 1.16 (1.08, 1.24)</p><p>&nbsp;</p><p><em>Norgestrel</em></p><p>&harr; C<sub>max</sub> 1.10 (1.02, 1.18)</p><p>&harr; AUC 1.09 (1.01, 1.18)</p><p>&harr; C<sub>min</sub> 1.11 (1.03, 1.20)</p><p>&nbsp;</p><p><em>Ethinylestradiol</em></p><p>&harr; C<sub>max</sub> 1.22 (1.15, 1.29)</p><p>&harr; AUC 1.11 (1.07, 1.16)</p><p>&harr; C<sub>min</sub> 1.02 (0.93, 1.12)</p></td><td style="vertical-align:top"><p>No dose adjustment of Vemlidy or norgestimate/ethinyl estradiol is required.</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp; All interaction studies are conducted in healthy volunteers.</p><p>b&nbsp;&nbsp;&nbsp; All No Effect Boundaries are 70%‑143%.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with emtricitabine/tenofovir alafenamide fixed‑dose combination tablet.</p><p>d&nbsp;&nbsp;&nbsp; A sensitive CYP3A4&nbsp;substrate.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed‑dose combination tablet.</p><p>f&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed‑dose combination tablet.</p><p>g&nbsp;&nbsp;&nbsp; The predominant circulating nucleoside metabolite of sofosbuvir.</p><p>h&nbsp;&nbsp;&nbsp; Study conducted with tenofovir alafenamide 40&nbsp;mg and emtricitabine 200&nbsp;mg.</p><p>i&nbsp;&nbsp;&nbsp;&nbsp; Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV&nbsp;infected patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>A moderate amount of data on pregnant women exposed to tenofovir alafenamide (between 300‑1000 pregnancy outcomes) indicate no malformative or feto/neonatal toxicity.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3).</p><p>&nbsp;</p><p>The use of tenofovir alafenamide may be considered during pregnancy, if necessary.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>Based on published data, tenofovir alafenamide and tenofovir are excreted in human milk at low levels in women administered with tenofovir alafenamide. There is insufficient information on the effects of tenofovir in newborns/infants.</p><p>&nbsp;</p><p>A risk to the breast‑fed newborns/infants cannot be excluded; therefore, Vemlidy should not be used during breast‑feeding.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No human data on the effect of tenofovir alafenamide on fertility are available. Animal studies do not indicate harmful effects of tenofovir alafenamide on fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vemlidy may have minor influence on the ability to drive and use machines.&nbsp; Patients should be informed that dizziness has been reported during treatment with tenofovir alafenamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>Assessment of adverse reactions is based on clinical study data and postmarketing data. In pooled safety data from 2 controlled&nbsp;Phase&nbsp;3 studies (GS‑US-320-0108 and GS-US-320-0110; &ldquo;<em>Study 108</em>&rdquo; and &ldquo;<em>Study 110</em>&rdquo;, respectively), the most frequently reported adverse reactions at Week 96 analysis were headache (12%), nausea (6%), and fatigue (6%). After Week&nbsp;96, patients either remained on their original blinded treatment up to Week 144 or received open-label tenofovir alafenamide.</p><p>&nbsp;</p><p>The safety profile of tenofovir alafenamide was similar in virologically suppressed patients switching from tenofovir disoproxil to tenofovir alafenamide in <em>Study 108</em>, <em>Study 110 </em>and a controlled Phase 3 study GS-US-320-4018 <em>(</em>&ldquo;<em>Study 4018</em>&rdquo;<em>).</em> Changes in lipid laboratory tests were observed in these studies following a switch from tenofovir disoproxil (see section 5.1).</p><p>&nbsp;</p><p><u>Tabulated summary of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions have been identified with tenofovir alafenamide in patients with CHB (Table&nbsp;2).&nbsp; The adverse reactions are listed below by body system organ class and frequency based on the Week&nbsp;96 analysis.&nbsp; Frequencies are defined as follows: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10) or uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100).</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Adverse Reactions Identified with Tenofovir Alafenamide</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:584px"><thead><tr><td colspan="2"><p><strong><em>System organ class</em></strong></p></td></tr><tr><td><p><strong>Frequency</strong></p></td><td><p><strong>Adverse reaction </strong></p></td></tr></thead><tbody><tr><td colspan="2"><p><em>Nervous system disorders</em></p></td></tr><tr><td><p>Very common</p></td><td><p>Headache</p></td></tr><tr><td><p>Common</p></td><td><p>Dizziness</p></td></tr><tr><td colspan="2"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td><p>Common</p></td><td><p>Diarrhoea, vomiting, nausea, abdominal pain, abdominal distension, flatulence</p></td></tr><tr><td colspan="2"><p><em>Hepatobiliary disorders</em></p></td></tr><tr><td><p>Common</p></td><td><p>Increased&nbsp;ALT</p></td></tr><tr><td colspan="2"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td><p>Common</p></td><td><p>Rash, pruritus</p></td></tr><tr><td><p>Uncommon</p></td><td><p>Angioedema<sup>1</sup>, urticaria<sup>1</sup></p></td></tr><tr><td colspan="2"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td><p>Common</p></td><td><p>Arthralgia</p></td></tr><tr><td colspan="2"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td><p>Common</p></td><td><p>Fatigue</p></td></tr></tbody></table><p>1- Adverse reaction identified through post-marketing surveillance for tenofovir alafenamide-containing products<strong>.</strong></p><p>&nbsp;</p><p>In the open-label Phase 2 study (GS-US-320-4035; &ldquo;<em>Study 4035</em>&rdquo;) to evaluate the efficacy and safety of switching from another antiviral regimen to tenofovir alafenamide in virologically suppressed HBV infected patients, small median increases in fasting total cholesterol, direct low density lipoprotein (LDL), high density lipoprotein (HDL), &nbsp;and triglycerides from baseline to Week 96 were observed in &nbsp;patients with moderate or severe renal impairment (Part A Cohort 1) and patients with moderate or severe hepatic impairment (Part B), consistent with changes observed in <em>Studies 108 and 110</em>. Small median decreases in total cholesterol, LDL and triglycerides were</p><p>&nbsp;</p><p>&nbsp;observed in patients with ESRD on hemodialysis in Part A Cohort 2, while small median increases were observed in HDL from baseline to Week 96. Median (Q1, Q3) change from baseline at Week 96 in total cholesterol to HDL ratio was</p><p>0.1 (-0.4, 0.4) in the moderate or severe renal impairment group, and -0.4 (-0.8,-0.1) in patients with ESRD on hemodialysis and 0.1 (-0.2, 0.4) in patients with moderate or severe hepatic impairment.</p><p>&nbsp;</p><p><em>Metabolic parameters</em></p><p>Body weight and levels of blood lipids and glucose may increase during therapy.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p>In <em>Study 4035</em> in virologically suppressed patients with moderate to severe renal impairment (eGFR by Cockcroft-Gault method 15 to 59&nbsp;mL/min; Part A, Cohort 1, N&nbsp;=&nbsp;78), end stage renal disease (ESRD) (eGFR&nbsp;&lt;&nbsp;15&nbsp;mL/min) on haemodialysis (Part A, Cohort 2, N&nbsp;=&nbsp;15), and/or moderate to severe hepatic impairment (Child-Pugh Class B or C at screening or by history; Part B, N&nbsp;=&nbsp;31) who switched from another antiviral regimen to tenofovir alafenamide, no additional adverse reactions to tenofovir alafenamide were identified through Week&nbsp;96.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>The safety of tenofovir alafenamide was evaluated in 88 HBV‑infected treatment-na&iuml;ve and treatment-experienced paediatric patients between the ages of 12 to &lt;&nbsp;18 years weighing &ge;&nbsp;35&nbsp;kg (tenofovir alafenamide group N=47, placebo group N=23) and 6 to &lt;&nbsp;12 years weighing &ge;&nbsp;25&nbsp;kg (tenofovir alafenamide group N=12, placebo group N=6) through Week 24 in a randomised, double-blind, placebo-controlled clinical study GS‑US‑320‑1092 <em>(</em>&ldquo;<em>Study 1092</em>&rdquo;<em>)</em>. After the double-blind phase, patients were switched to open-label tenofovir alafenamide at Week&nbsp;24. The safety profile of tenofovir alafenamide in paediatric patients was comparable to that in adults. Reductions in bone mineral density (BMD &ge;&nbsp;4%) of the lumbar spine and of whole body have been reported in some paediatric patients 6 years of age and older weighing at least 25&nbsp;kg who received tenofovir alafenamide for up to 48 weeks (see sections 4.4 and 5.1).</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. &nbsp;It allows continued monitoring of the benefit/risk balance of the medicinal product. &nbsp;Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:-23.8pt;margin-top:10.7pt;
 width:521.25pt;height:61.1pt;z-index:251657216;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQC2gziS/gAAAOEBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRQU7DMBBF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">
 <v:textbox style='mso-next-textbox:#Text_x0020_Box_x0020_2;
  mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center&nbsp;: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><p><!--[if gte vml 1]><v:shape
 id="_x0000_s1027" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:-27.7pt;margin-top:10.9pt;width:525.15pt;height:20.65pt;
 z-index:251658240'>
 <v:textbox style='mso-next-textbox:#_x0000_s1027'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If overdose occurs the patient must be monitored for evidence of toxicity (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Treatment of overdose with tenofovir alafenamide consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.</p><p>&nbsp;</p><p>Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately&nbsp;54%. It is not known whether tenofovir can be removed by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antiviral for systemic use, nucleoside and nucleotide reverse transcriptase inhibitors; ATC&nbsp;code: J05AF13.</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Tenofovir alafenamide is a phosphonamidate prodrug of tenofovir (2&rsquo;‑deoxyadenosine monophosphate analogue).&nbsp; Tenofovir alafenamide enters primary hepatocytes by passive diffusion and by the hepatic uptake transporters OATP1B1 and OATP1B3. Tenofovir alafenamide is primarily hydrolysed to form tenofovir by carboxylesterase&nbsp;1 in primary hepatocytes. Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate.&nbsp; Tenofovir diphosphate inhibits HBV replication through incorporation into viral&nbsp;DNA by the HBV&nbsp;reverse transcriptase, which results in DNA&nbsp;chain termination.</p><p>&nbsp;</p><p>Tenofovir has activity that is specific to HBV and HIV (HIV‑1 and HIV‑2). Tenofovir diphosphate is a weak inhibitor of mammalian DNA&nbsp;polymerases that include mitochondrial DNA&nbsp;polymerase&nbsp;&gamma; and there is no evidence of mitochondrial toxicity <em>in&nbsp;vitro</em> based on several assays including mitochondrial DNA&nbsp;analyses.</p><p>&nbsp;</p><p><u>Antiviral activity</u></p><p>&nbsp;</p><p>The antiviral activity of tenofovir alafenamide was assessed in HepG2&nbsp;cells against a panel of HBV&nbsp;clinical isolates representing genotypes&nbsp;A‑H. The EC<sub>50</sub> (50%&nbsp;effective concentration) values for tenofovir alafenamide ranged from 34.7 to 134.4&nbsp;nM, with an overall mean EC<sub>50</sub> of 86.6&nbsp;nM.&nbsp; The&nbsp;CC<sub>50</sub> (50%&nbsp;cytotoxicity concentration) in HepG2&nbsp;cells was &gt;&nbsp;44,400&nbsp;nM.</p><p><u>&nbsp;</u></p><p><u>Resistance</u></p><p>&nbsp;</p><p>In patients receiving tenofovir alafenamide, sequence analysis was performed on paired baseline and on‑treatment HBV&nbsp;isolates for patients who either experienced virologic breakthrough (2&nbsp;consecutive visits with HBV&nbsp;DNA &ge;&nbsp;69&nbsp;IU/mL after having been &lt;&nbsp;69&nbsp;IU/mL, or 1.0&nbsp;log<sub>10</sub> or greater increase in HBV&nbsp;DNA from nadir) or patients with HBV&nbsp;DNA &ge;&nbsp;69&nbsp;IU/mL at Week 48, or Week&nbsp;96 or at early discontinuation at or after Week&nbsp;24.&nbsp;</p><p>&nbsp;</p><p>In a pooled analysis of patients receiving tenofovir alafenamide in <em>Study 108</em> and <em>Study 110</em> at Week&nbsp;48 (N&nbsp;=&nbsp;20) and Week&nbsp;96 (N&nbsp;=&nbsp;72), no amino acid substitutions associated with resistance to tenofovir alafenamide were identified in these isolates (genotypic and phenotypic analyses).</p><p>&nbsp;</p><p>In virologically suppressed patients receiving tenofovir alafenamide following switch from tenofovir disoproxil&nbsp; treatment in <em>Study 4018</em>, through 96 weeks of tenofovir alafenamide treatment one patient in the tenofovir alafenamide-tenofovir alafenamide group experienced a virologic blip (one visit with HBV DNA&nbsp;&ge;&nbsp;69&nbsp;IU/mL) and one patient in the tenofovir disoproxil-tenofovir alafenamide group experienced a virologic breakthrough. No HBV amino acid substitutions associated with resistance to tenofovir alafenamide or tenofovir disoproxil were detected through 96 weeks of treatment.</p><p>&nbsp;</p><p>In paediatric <em>Study 1092</em>, 30 patients aged 12 to &lt;&nbsp;18 years and 9 patients aged 6 to &lt;&nbsp;12 years receiving tenofovir alafenamide qualified for resistance analysis at Week 24. No HBV amino acid substitutions associated with resistance to tenofovir alafenamide were detected through 24 weeks of treatment. At Week 48, 31 patients aged 12 to &lt;&nbsp;18 years and 12 patients aged 6 to &lt;&nbsp;12 years qualified for resistance analysis (both tenofovir alafenamide group and placebo roll over to tenofovir alafenamide group at Week 24). No HBV amino acid substitutions associated with resistance to tenofovir alafenamide were detected through 48 weeks of treatment.</p><p>&nbsp;</p><p><em>Cross‑resistance</em></p><p>The antiviral activity of tenofovir alafenamide was evaluated against a panel of isolates containing nucleos(t)ide reverse transcriptase inhibitor mutations in HepG2&nbsp;cells. HBV&nbsp;isolates expressing the rtV173L, rtL180M, and rtM204V/I&nbsp;substitutions associated with resistance to lamivudine remained susceptible to tenofovir alafenamide (&lt;&nbsp;2‑fold change in EC<sub>50</sub>). HBV&nbsp;isolates expressing the rtL180M, rtM204V plus rtT184G, rtS202G, or rtM250V&nbsp;substitutions associated with resistance to entecavir remained susceptible to tenofovir alafenamide. HBV&nbsp;isolates expressing the rtA181T, rtA181V, or rtN236T&nbsp;single substitutions associated with resistance to adefovir remained susceptible to tenofovir alafenamide; however, the HBV&nbsp;isolate expressing rtA181V plus rtN236T exhibited reduced susceptibility to tenofovir alafenamide (3.7‑fold change in EC<sub>50</sub>). The clinical relevance of these substitutions is not known.</p><p>&nbsp;</p><p><u>Clinical data</u></p><p>&nbsp;</p><p>The efficacy and safety of tenofovir alafenamide in patients with CHB are based on 48‑ and 96‑week data from two randomised, double‑blind, active‑controlled studies, <em>Study&nbsp;108</em> and <em>Study&nbsp;110</em>. The safety of tenofovir alafenamide is also supported by pooled data from patients in <em>Studies</em>&nbsp;<em>108</em> and <em>110</em> who remained on blinded treatment from Week&nbsp;96 through Week&nbsp;144 and additionally from patients in the open-label phase of <em>Studies</em>&nbsp;<em>108</em> and <em>110</em> from Week&nbsp;96 through Week&nbsp;144 (N&nbsp;=&nbsp;360 remained on tenofovir alafenamide; N&nbsp;=&nbsp;180 switched from tenofovir disoproxil to tenofovir alafenamide at Week&nbsp;96).</p><p>&nbsp;</p><p>In <em>Study&nbsp;108,</em> HBeAg‑negative treatment‑na&iuml;ve and treatment‑experienced patients with compensated liver function were randomised in a 2:1&nbsp;ratio to receive tenofovir alafenamide (25&nbsp;mg; N&nbsp;=&nbsp;285) once daily or tenofovir disoproxil (245&nbsp;mg; N&nbsp;=&nbsp;140) once daily. The mean age was 46&nbsp;years, 61% were male, 72% were Asian, 25% were White and 2% (8 patients) were Black. 24%, 38%, and 31% had HBV&nbsp;genotype&nbsp;B, C, and D, respectively.&nbsp; 21% were treatment‑experienced (previous treatment with oral antivirals, including entecavir (N&nbsp;=&nbsp;41), lamivudine (N&nbsp;=&nbsp;42), tenofovir disoproxil (N&nbsp;=&nbsp;21), or other (N&nbsp;=&nbsp;18)). At baseline, mean plasma HBV&nbsp;DNA was 5.8&nbsp;log<sub>10</sub>&nbsp;IU/mL, mean serum&nbsp;ALT was 94&nbsp;U/L, and 9% of patients had a history of cirrhosis.</p><p>&nbsp;</p><p>In <em>Study&nbsp;110,</em> HBeAg‑positive treatment‑na&iuml;ve and treatment‑experienced patients with compensated liver function were randomised in a 2:1&nbsp;ratio to receive tenofovir alafenamide (25&nbsp;mg; N&nbsp;=&nbsp;581) once daily or tenofovir disoproxil (245&nbsp;mg; N&nbsp;=&nbsp;292) once daily.&nbsp; The mean age was 38&nbsp;years, 64% were male, 82% were Asian, 17% were White and &lt;&nbsp;1% (5 patients) were Black. 17%, 52%, and 23% had HBV&nbsp;genotype&nbsp;B, C, and D, respectively. 26% were treatment‑experienced (previous treatment with oral antivirals, including adefovir (N&nbsp;=&nbsp;42), entecavir (N&nbsp;=&nbsp;117), lamivudine (N&nbsp;=&nbsp;84), telbivudine (N&nbsp;=&nbsp;25), tenofovir disoproxil (N&nbsp;=&nbsp;70), or other (N&nbsp;=&nbsp;17)). At baseline, mean plasma HBV&nbsp;DNA was 7.6&nbsp;log<sub>10</sub>&nbsp;IU/mL, mean serum&nbsp;ALT was 120&nbsp;U/L, and 7% of patients had a history of cirrhosis.</p><p>&nbsp;</p><p>The primary efficacy endpoint in both studies was the proportion of patients with plasma HBV&nbsp;DNA levels below 29&nbsp;IU/mL at Week&nbsp;48. Tenofovir alafenamide met the non‑inferiority criteria in achieving HBV&nbsp;DNA less than 29&nbsp;IU/mL when compared to tenofovir disoproxil. Treatment outcomes of <em>Study&nbsp;108</em> and <em>Study&nbsp;110</em> through Week&nbsp;48 are presented in Table&nbsp;3 and Table&nbsp;4.</p><p>&nbsp;</p><p><strong>Table&nbsp;3: HBV&nbsp;DNA Efficacy Parameters at Week&nbsp;48<sup>a</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Study&nbsp;108</em></strong><strong> (HBeAg‑Negative)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Study&nbsp;110</em></strong><strong> (HBeAg‑Positive)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>TAF</strong><br />(N&nbsp;=&nbsp;285)</p></td><td style="vertical-align:top"><p><strong>TDF</strong><br />(N&nbsp;=&nbsp;140)</p></td><td style="vertical-align:top"><p><strong>TAF</strong><br />(N&nbsp;=&nbsp;581)</p></td><td style="vertical-align:top"><p><strong>TDF</strong><br />(N&nbsp;=&nbsp;292)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>HBV&nbsp;DNA &lt;&nbsp;29&nbsp;IU/mL</strong></p></td><td><p>94%</p></td><td><p>93%</p></td><td><p>64%</p></td><td><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference<sup>b</sup></p></td><td colspan="2"><p>1.8% (95%&nbsp;CI&nbsp;=&nbsp;‑3.6% to 7.2%)</p></td><td colspan="2"><p>‑3.6% (95%&nbsp;CI&nbsp;=&nbsp;‑9.8% to 2.6%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>HBV&nbsp;DNA &ge;&nbsp;29&nbsp;IU/mL</strong></p></td><td><p>2%</p></td><td><p>3%</p></td><td><p>31%</p></td><td><p>30%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline HBV&nbsp;DNA</strong></p><p>&lt;&nbsp;7&nbsp;log<sub>10</sub>&nbsp;IU/mL</p><p>&ge;&nbsp;7&nbsp;log<sub>10</sub>&nbsp;IU/mL</p></td><td><p>&nbsp;</p><p>96% (221/230)</p><p>85% (47/55)</p></td><td><p>&nbsp;</p><p>92% (107/116)</p><p>96% (23/24)</p></td><td><p>N/A</p></td><td><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline HBV&nbsp;DNA</strong></p><p>&lt;&nbsp;8&nbsp;log<sub>10</sub>&nbsp;IU/mL</p><p>&ge;&nbsp;8&nbsp;log<sub>10</sub>&nbsp;IU/mL</p></td><td><p>N/A</p></td><td><p>N/A</p></td><td><p>&nbsp;</p><p>82% (254/309)</p><p>43% (117/272)</p></td><td><p>&nbsp;</p><p>82% (123/150)</p><p>51% (72/142)</p></td></tr><tr><td style="vertical-align:top"><p>Nucleoside na&iuml;ve<sup>c</sup></p><p>Nucleoside experienced</p></td><td><p>94% (212/225)</p><p>93% (56/60)</p></td><td><p>93% (102/110)</p><p>93% (28/30)</p></td><td><p>68% (302/444)</p><p>50% (69/137)</p></td><td><p>70% (156/223)</p><p>57% (39/69)</p></td></tr><tr><td style="vertical-align:top"><p><strong>No Virologic data<br />at Week&nbsp;48</strong></p></td><td><p>4%</p></td><td><p>4%</p></td><td><p>5%</p></td><td><p>3%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to lack of efficacy</p></td><td><p>0</p></td><td><p>0</p></td><td><p>&lt;&nbsp;1%</p></td><td><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to AE or death</p></td><td><p>1%</p></td><td><p>1%</p></td><td><p>1%</p></td><td><p>1%</p></td></tr><tr><td style="vertical-align:top"><p>Discontinued study drug due to other reasons<sup>d</sup></p></td><td><p>2%</p></td><td><p>3%</p></td><td><p>3%</p></td><td><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Missing data during window but on study drug</p></td><td><p>&lt;&nbsp;1%</p></td><td><p>1%</p></td><td><p>&lt;&nbsp;1%</p></td><td><p>0</p></td></tr></tbody></table><p>N/A&nbsp;=&nbsp;not applicable</p><p>TDF&nbsp;=&nbsp;tenofovir disoproxil</p><p>TAF = tenofovir alafenamide</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; Missing&nbsp;=&nbsp;failure analysis.</p><p>b&nbsp;&nbsp;&nbsp; Adjusted by baseline plasma HBV&nbsp;DNA categories and oral antiviral treatment status strata.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; Treatment‑na&iuml;ve patients received &lt;&nbsp;12&nbsp;weeks of oral antiviral treatment with any nucleoside or nucleotide analogue including tenofovir disoproxil or tenofovir alafenamide.</p><p>d&nbsp;&nbsp;&nbsp; Includes patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy, e.g. withdrew consent, loss to follow‑up, etc.</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Additional Efficacy Parameters at Week&nbsp;48<sup>a</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Study&nbsp;108</em></strong><strong> (HBeAg‑Negative)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Study&nbsp;110</em></strong><strong> (HBeAg‑Positive)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>TAF</strong><br />(N&nbsp;=&nbsp;285)</p></td><td style="vertical-align:top"><p><strong>TDF</strong><br />(N&nbsp;=&nbsp;140)</p></td><td style="vertical-align:top"><p><strong>TAF</strong><br />(N&nbsp;=&nbsp;581)</p></td><td style="vertical-align:top"><p><strong>TDF</strong><br />(N&nbsp;=&nbsp;292)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ALT</strong></p><p>Normalised ALT (Central lab)<sup>b</sup></p></td><td style="vertical-align:bottom"><p>83%</p></td><td style="vertical-align:bottom"><p>75%</p></td><td style="vertical-align:bottom"><p>72%</p></td><td style="vertical-align:bottom"><p>67%</p></td></tr><tr><td style="vertical-align:top"><p>Normalised ALT (AASLD)<sup>c</sup></p></td><td style="vertical-align:bottom"><p>50%</p></td><td style="vertical-align:bottom"><p>32%</p></td><td style="vertical-align:bottom"><p>45%</p></td><td style="vertical-align:bottom"><p>36%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Serology</strong></p><p>HBeAg loss / seroconversion<sup>d</sup></p></td><td style="vertical-align:bottom"><p>N/A</p></td><td style="vertical-align:bottom"><p>N/A</p></td><td style="vertical-align:bottom"><p>14% / 10%</p></td><td style="vertical-align:bottom"><p>12% / 8%</p></td></tr><tr><td style="vertical-align:top"><p>HBsAg loss / seroconversion</p></td><td><p>0 / 0</p></td><td><p>0 / 0</p></td><td><p>1% / 1%</p></td><td><p>&lt;&nbsp;1% / 0</p></td></tr></tbody></table><p>N/A&nbsp;=&nbsp;not applicable</p><p>TDF&nbsp;=&nbsp;tenofovir disoproxil</p><p>TAF = tenofovir alafenamide</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; Missing&nbsp;=&nbsp;failure analysis.</p><p>b&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above upper limit of normal&nbsp;(ULN) of the central laboratory range at baseline. Central laboratory ULN for ALT are as follows: &le;&nbsp;43&nbsp;U/L for males aged 18 to &lt;&nbsp;69&nbsp;years and &le;&nbsp;35&nbsp;U/L for males &ge;&nbsp;69&nbsp;years; &le;&nbsp;34&nbsp;U/L for females 18 to &lt;&nbsp;69&nbsp;years and &le;&nbsp;32&nbsp;U/L for females &ge;&nbsp;69&nbsp;years.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the 2016 American Association of the Study of Liver Diseases (AASLD) criteria (&gt;&nbsp;30&nbsp;U/L males and &gt;&nbsp;19&nbsp;U/L females) at baseline.</p><p>d&nbsp;&nbsp;&nbsp; The population used for serology analysis included only patients with antigen (HBeAg) positive and antibody (HBeAb) negative or missing at baseline.</p><p><em>&nbsp;</em></p><p><em>Experience beyond 48&nbsp;weeks in Study&nbsp;108 and Study&nbsp;110</em></p><p>At Week&nbsp;96, viral suppression as well as biochemical and serological responses were maintained with continued tenofovir alafenamide treatment (see Table&nbsp;5).</p><p>&nbsp;</p><p><strong>Table&nbsp;5: HBV&nbsp;DNA and Additional Efficacy Parameters at Week&nbsp;96<sup>a</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Study&nbsp;108</em></strong><strong> (HBeAg‑Negative)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong><em>Study&nbsp;110</em></strong><strong> (HBeAg‑Positive)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>TAF</strong><br />(N&nbsp;=&nbsp;285)</p></td><td style="vertical-align:top"><p><strong>TDF</strong><br />(N&nbsp;=&nbsp;140)</p></td><td style="vertical-align:top"><p><strong>TAF</strong><br />(N&nbsp;=&nbsp;581)</p></td><td style="vertical-align:top"><p><strong>TDF</strong><br />(N&nbsp;=&nbsp;292)</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>HBV&nbsp;DNA &lt;&nbsp;29&nbsp;IU/mL</strong></p></td><td><p>90%</p></td><td><p>91%</p></td><td><p>73%</p></td><td><p>75%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline HBV&nbsp;DNA</strong></p><p>&lt;&nbsp;7&nbsp;log<sub>10</sub>&nbsp;IU/mL</p><p>&ge;&nbsp;7&nbsp;log<sub>10</sub>&nbsp;IU/mL</p></td><td><p>&nbsp;</p><p>90% (207/230)</p><p>91% (50/55)</p></td><td><p>&nbsp;</p><p>91% (105/116)</p><p>92% (22/24)</p></td><td><p>N/A</p></td><td><p>N/A</p></td></tr><tr><td style="vertical-align:top"><p><strong>Baseline HBV&nbsp;DNA</strong></p><p>&lt;&nbsp;8&nbsp;log<sub>10</sub>&nbsp;IU/mL</p><p>&ge;&nbsp;8&nbsp;log<sub>10</sub>&nbsp;IU/mL</p></td><td><p>N/A</p></td><td><p>N/A</p></td><td><p>&nbsp;</p><p>84% (260/309)</p><p>60% (163/272)</p></td><td><p>&nbsp;</p><p>81% (121/150)</p><p>68% (97/142)</p></td></tr><tr><td style="vertical-align:top"><p>Nucleoside‑na&iuml;ve<sup>b</sup></p><p>Nucleoside‑experienced</p></td><td><p>90% (203/225)</p><p>90% (54/60)</p></td><td><p>92% (101/110)</p><p>87% (26/30)</p></td><td><p>75% (331/444)</p><p>67% (92/137)</p></td><td><p>75% (168/223)</p><p>72% (50/69)</p></td></tr><tr><td style="vertical-align:top"><p><strong>ALT</strong></p><p>Normalised ALT (Central lab)<sup>c</sup></p><p>Normalised ALT (AASLD)<sup>d</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p><p>81%</p><p>50%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>71%</p><p>40%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>75%</p><p>52%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>68%</p><p>42%</p></td></tr><tr><td style="vertical-align:top"><p><strong>Serology</strong></p><p>HBeAg loss / seroconversion<sup>e</sup></p></td><td style="vertical-align:bottom"><p>N/A</p></td><td style="vertical-align:bottom"><p>N/A</p></td><td style="vertical-align:bottom"><p>22% / 18%</p></td><td style="vertical-align:bottom"><p>18% / 12%</p></td></tr><tr><td style="vertical-align:top"><p>HBsAg loss / seroconversion</p></td><td style="vertical-align:top"><p>&lt;&nbsp;1% / &lt;&nbsp;1%</p></td><td style="vertical-align:top"><p>0 / 0</p></td><td style="vertical-align:top"><p>1% / 1%</p></td><td style="vertical-align:top"><p>1% / 0</p></td></tr></tbody></table><p>N/A&nbsp;=&nbsp;not applicable</p><p>TDF&nbsp;=&nbsp;tenofovir disoproxil</p><p>TAF = tenofovir alafenamide</p><p>a&nbsp;&nbsp;&nbsp;&nbsp; Missing&nbsp;=&nbsp;failure analysis</p><p>b&nbsp;&nbsp;&nbsp; Treatment‑na&iuml;ve patients received &lt;&nbsp;12&nbsp;weeks of oral antiviral treatment with any nucleoside or nucleotide analogue including tenofovir disoproxil or tenofovir alafenamide.</p><p>c&nbsp;&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the central laboratory range at baseline. Central laboratory ULN for ALT are as follows: &le;&nbsp;43&nbsp;U/L for males aged 18 to &lt;&nbsp;69&nbsp;years and &le;&nbsp;35&nbsp;U/L for males &ge;&nbsp;69&nbsp;years; &le;&nbsp;34&nbsp;U/L for females 18 to &lt;&nbsp;69&nbsp;years and &le;&nbsp;32&nbsp;U/L for females &ge;&nbsp;69&nbsp;years.</p><p>d&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the 2016 AASLD criteria (&gt;&nbsp;30&nbsp;U/L males and &gt;&nbsp;19&nbsp;U/L females) at baseline.</p><p>e&nbsp;&nbsp;&nbsp;&nbsp; The population used for serology analysis included only patients with antigen (HBeAg) positive and antibody (HBeAb) negative or missing at baseline.</p><p>&nbsp;</p><p><em>Changes in measures of bone mineral density </em><em>in Study&nbsp;108 and Study&nbsp;110</em></p><p>In both studies tenofovir alafenamide was associated with smaller mean percentage decreases in BMD (as measured by hip and lumbar spine dual energy X&nbsp;ray absorptiometry [DXA] analysis) compared to tenofovir disoproxil after 96&nbsp;weeks of treatment.</p><p>&nbsp;</p><p>In patients who remained on blinded treatment beyond Week&nbsp;96, mean percentage change in BMD in each group at Week&nbsp;144 was similar to that at Week&nbsp;96. &nbsp;In the open-label phase of both studies, mean percentage change in BMD from Week&nbsp;96 to Week&nbsp;144 in patients who remained on tenofovir alafenamide was +0.4% at the lumbar spine and -0.3% at the total hip, compared to +2.0% at the lumbar spine and +0.9% at the total hip in those who switched from tenofovir disoproxil to tenofovir alafenamide at Week&nbsp;96.</p><p>&nbsp;</p><p><em>Changes in measures of renal function </em><em>in Study&nbsp;108 and Study&nbsp;110</em></p><p><em>&nbsp;</em></p><p>In both studies tenofovir alafenamide was associated with smaller changes in renal safety parameters (smaller median reductions in estimated CrCl by Cockcroft-Gault and smaller median percentage increases in urine retinol binding protein to creatinine ratio and urine beta‑2‑microglobulin to creatinine ratio) compared to tenofovir disoproxil after 96&nbsp;weeks of treatment (see also section&nbsp;4.4).</p><p>&nbsp;</p><p>In patients who remained on blinded treatment beyond Week&nbsp;96 in <em>Studies</em>&nbsp;<em>108</em> and <em>110,</em> changes from baseline in renal laboratory parameter values in each group at Week&nbsp;144 were similar to those at Week&nbsp;96. &nbsp;In the open-label phase of <em>Studies</em>&nbsp;<em>108</em> and <em>110,</em> the mean (SD) change in serum creatinine from Week&nbsp;96 to Week&nbsp;144 was&nbsp; &nbsp;+0.002 (0.0924)&nbsp;mg/dL in those who remained on tenofovir alafenamide, compared to -0.018 (0.0691)&nbsp;mg/dL in those who switched from tenofovir disoproxil to tenofovir alafenamide at Week&nbsp;96. In the open-label phase, the median change in eGFR from Week&nbsp;96 to Week&nbsp;144 was ‑1.2&nbsp;mL/min in patients who remained on tenofovir alafenamide, compared to +4.2&nbsp;mL/min in patients who switched from tenofovir disoproxil to tenofovir alafenamide at Week&nbsp;96.</p><p>&nbsp;</p><p><em>Changes in lipid laboratory tests in Study 108 and Study 110</em></p><p>In a pooled analysis of <em>Studies 108</em> and <em>110</em>, median changes in fasting lipid parameters from baseline to Week 96 were observed in both treatment groups. For patients who switched to open label tenofovir alafenamide at Week 96, changes from double-blind baseline for patients randomised initially to tenofovir alafenamide and tenofovir disoproxil at Week 96 and Week 144 in total cholesterol, HDL‑cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio are presented in Table 6. At Week 96, the end of the double-blind phase, decreases in median fasting total cholesterol and HDL, and increases in median fasting direct LDL and triglycerides were observed in the tenofovir alafenamide group, while the tenofovir disoproxil group demonstrated median reductions in all parameters.</p><p>&nbsp;</p><p>In the open-label phase of <em>Studies 108</em> and <em>110</em>, where patients switched to open-label tenofovir alafenamide at Week 96, lipid parameters at Week 144 in patients who remained on tenofovir alafenamide were similar to those at Week 96, whereas median increases in fasting total cholesterol, direct LDL, HDL, and triglycerides were observed in patients who switched from tenofovir disoproxil to tenofovir alafenamide at Week 96. In the open label phase, median (Q1, Q3) change from Week 96 to Week 144 in total cholesterol to HDL ratio was 0.0 (-0.2, 0.4) in patients who remained on tenofovir alafenamide and 0.2 (-0.2, 0.6) in patients who switched from tenofovir disoproxil to tenofovir alafenamide at Week&nbsp;96.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table 6: Median Changes from Double-Blind Baseline in Lipid Laboratory Tests at Weeks&nbsp;96&nbsp;and&nbsp; 144 for Patients Who Switched to Open-Label Tenofovir Alafenamide at Week 96</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>TAF-TAF</strong></p><p><strong>(N=360)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Double blind baseline</strong></p></td><td style="vertical-align:top"><p><strong>Week 96</strong></p></td><td style="vertical-align:top"><p><strong>Week 144</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Median (Q1, Q3)</p><p>(mg/dL)</p></td><td style="vertical-align:top"><p>Median change (Q1, Q3)</p><p>(mg/dL)</p></td><td style="vertical-align:top"><p>Median change (Q1, Q3)</p><p>(mg/dL)</p></td></tr><tr><td style="vertical-align:top"><p>Total Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>185 (166, 210)</p></td><td style="vertical-align:top"><p>0 (-18, 17)</p></td><td style="vertical-align:top"><p>0 (-16, 18)</p></td></tr><tr><td style="vertical-align:top"><p>HDL-Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>59 (49, 72)</p></td><td style="vertical-align:top"><p>-5 (-12, 1)<sup>a</sup></p></td><td style="vertical-align:top"><p>-5 (-12,2)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>LDL-Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>113 (95, 137)</p></td><td style="vertical-align:top"><p>6 (-8, 21)<sup>a</sup></p></td><td style="vertical-align:top"><p>8 (-6, 24)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides (fasted)</p></td><td style="vertical-align:top"><p>87 (67, 122)</p></td><td style="vertical-align:top"><p>8 (-12, 28)<sup>a</sup></p></td><td style="vertical-align:top"><p>11 (-11, 40)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Total Cholesterol to HDL ratio</p></td><td style="vertical-align:top"><p>3.1 (2.6, 3.9)</p></td><td style="vertical-align:top"><p>0.2 (0.0, 0.6)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.3 (0.0, 0.7)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>TDF-TAF</strong></p><p><strong>(N=180)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Double blind baseline</strong></p></td><td style="vertical-align:top"><p><strong>Week 96 </strong></p></td><td style="vertical-align:top"><p><strong>Week 144</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Median (Q1, Q3)</p><p>(mg/dL)</p></td><td style="vertical-align:top"><p>Median change (Q1, Q3)</p><p>(mg/dL)</p></td><td style="vertical-align:top"><p>Median change (Q1, Q3)</p><p>(mg/dL)</p></td></tr><tr><td style="vertical-align:top"><p>Total Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>189 (163, 215)</p></td><td style="vertical-align:top"><p>-23 (-40, -1)<sup>a</sup></p></td><td style="vertical-align:top"><p>1 (-17, 20)</p></td></tr><tr><td style="vertical-align:top"><p>HDL-Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>61 (49, 72)</p></td><td style="vertical-align:top"><p>-12 (-19, -3)<sup>a</sup></p></td><td style="vertical-align:top"><p>-8 (-15, -1)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>LDL-Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>120 (95, 140)</p></td><td style="vertical-align:top"><p>-7 (-25, 8)<sup>a</sup></p></td><td style="vertical-align:top"><p>9 (-5, 26)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides (fasted)</p></td><td style="vertical-align:top"><p>89 (69, 114)</p></td><td style="vertical-align:top"><p>-11 (-31, 11)<sup>a</sup></p></td><td style="vertical-align:top"><p>14 (-10, 43)<sup>b</sup></p></td></tr><tr><td style="vertical-align:top"><p>Total Cholesterol to HDL ratio</p></td><td style="vertical-align:top"><p>3.1 (2.5, 3.7)</p></td><td style="vertical-align:top"><p>0.2 (-0.1, 0.7)<sup>a</sup></p></td><td style="vertical-align:top"><p>0.4 (0.0, 1.0)<sup>b</sup></p></td></tr></tbody></table><p>TAF = tenofovir alafenamide</p><p>TDF = tenofovir disoproxil</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-value was calculated for change from double blind baseline at Week 96, from Wilcoxon Signed Rank test and was statistically significant (p &lt; 0.001).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; P-value was calculated for change from double blind baseline at Week 144, from Wilcoxon Signed Rank test and was statistically significant (p &lt; 0.001).</p><p>&nbsp;</p><p><em>Virologically suppressed adult patients in Study 4018</em></p><p>The efficacy and safety of tenofovir alafenamide in virologically suppressed adults with chronic hepatitis B is based on 48-week data from a randomised, double-blind, active-controlled study, <em>Study 4018</em> (N=243 on tenofovir alafenamide; N=245 on tenofovir disoproxil), including data from patients who participated in the open-label phase of <em>Study 4018</em> from Week 48 through Week 96 (N=235 remained on tenofovir alafenamide [TAF-TAF]; N=237 switched from tenofovir disoproxil to tenofovir alafenamide at Week 48 [TDF-TAF]).</p><p>In <em>Study</em> <em>4018</em> virologically suppressed adults with chronic hepatitis B (N=488) were enrolled who had been previously maintained on 245 mg tenofovir disoproxil once daily for at least 12 months, with HBV&nbsp;DNA&nbsp;&lt;&nbsp;lower limit of quantification (LLOQ) by local laboratory assessment for at least 12 weeks prior to screening and HBV DNA &lt; 20 IU/mL at screening. Patients were stratified by HBeAg status (HBeAg-positive or HBeAg-negative) and age (&ge; 50 or &lt; 50 years) and randomised in a 1:1 ratio to switch to 25&nbsp;mg tenofovir alafenamide (N=243) or remain on 245 mg tenofovir disoproxil once daily (N=245). Mean age was 51 years (22% were &ge; 60 years), 71% were male, 82% were Asian, 14% were White, and 68% were HBeAg‑negative. At baseline, median duration of prior tenofovir disoproxil treatment was 220 and 224 weeks in the tenofovir alafenamide and tenofovir disoproxil groups, respectively. Previous treatment with antivirals also included interferon (N=63), lamivudine (N=191), adefovir dipivoxil (N=185), entecavir (N=99), telbivudine (N=48), or other (N=23). At baseline, mean serum ALT was 27 U/L, median eGFR by Cockcroft-Gault was 90.5 mL/min; 16% of patients had a history of cirrhosis.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the proportion of patients with plasma HBV DNA levels&nbsp;&ge;&nbsp;20&nbsp;IU/mL at Week 48 (as determined by the modified US FDA Snapshot algorithm). Additional efficacy endpoints included the proportion of patients with HBV DNA levels &lt; 20 IU/mL, ALT normal and ALT normalisation, HBsAg loss and seroconversion, and HBeAg loss and seroconversion. Tenofovir alafenamide was non-inferior in the proportion of patients with HBV DNA &ge; 20 IU/mL at Week 48 when compared to tenofovir disoproxil&nbsp; as assessed by the modified US FDA Snapshot algorithm. Treatment outcomes (HBV DNA &lt; 20 IU/mL by missing=failure) at Week 48 between treatment groups were similar across subgroups by age, sex, race, baseline HBeAg status, and ALT.</p><p>&nbsp;</p><p>Treatment outcomes of <em>Study 4018</em> at Week 48 and Week 96 are presented in Table 7 and Table 8.</p><p>&nbsp;</p><p><strong>Table&nbsp;7: HBV&nbsp;DNA </strong><strong>Efficacy Parameters </strong><strong>at Week 48<sup>a,b&nbsp;</sup></strong><strong>and Week 96<sup>b,c</sup></strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>TAF</strong><br /><strong>(N=243)</strong></p></td><td style="vertical-align:bottom"><p><strong>TDF</strong><br /><strong>(</strong><strong>N</strong><strong>=245)</strong></p></td><td style="vertical-align:bottom"><p><strong>TAF-TAF</strong><br /><strong>(N=243)</strong></p></td><td style="vertical-align:bottom"><p><strong>TDF-TAF</strong><br /><strong>(N=245)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Week 48</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 96</strong></p></td></tr></thead><tbody><tr><td><p><strong>HBV DNA &ge; 20 IU/mL<sup>b,d</sup></strong></p></td><td><p>1 (0.4%)</p></td><td><p>1 (0.4%)</p></td><td><p>1 (0.4%)</p></td><td><p>1 (0.4%)</p></td></tr><tr><td><p>Treatment Difference<sup>e</sup></p></td><td colspan="2"><p>0.0% (95% CI = -1.9% to 2.0%)</p></td><td colspan="2" style="vertical-align:top"><p>0.0% (95% CI = -1.9% to 1.9%)</p></td></tr><tr><td><p><strong>HBV DNA &lt; 20&nbsp;IU/mL</strong></p></td><td><p>234 (96.3%)</p></td><td><p>236 (96.3%)</p></td><td><p>230 (94.7%)</p></td><td><p>230 (93.9%)</p></td></tr><tr><td><p>Treatment Difference<sup>e</sup></p></td><td colspan="2"><p>0.0% (95% CI = -3.7% to 3.7%)</p></td><td colspan="2" style="vertical-align:top"><p>0.9% (95% CI = -3.5% to 5.2%)</p></td></tr><tr><td><p><strong>No Virologic Data </strong></p></td><td><p>8 (3.3%)</p></td><td><p>8 (3.3%)</p></td><td><p>12 (4.9%)</p></td><td><p>14 (5.7%)</p></td></tr><tr><td><p>Discontinued Study Drug Due to AE or Death and Last Available HBV DNA &lt; 20 IU/mL</p></td><td><p>2 (0.8%)</p></td><td><p>0</p></td><td><p>3 (1.2%)</p></td><td><p>1 (0.4%)</p></td></tr><tr><td><p>Discontinued Study Drug Due to Other Reasons<sup>f</sup> and Last Available HBV DNA &lt; 20 IU/mL</p></td><td><p>6 (2.5%)</p></td><td><p>8 (3.3%)</p></td><td><p>7 (2.9%)</p></td><td><p>11 (4.5%)</p></td></tr><tr><td><p>Missing&nbsp;Data During Window but on Study Drug</p></td><td><p>0</p></td><td><p>0</p></td><td><p>2 (0.8%)</p></td><td><p>2 (0.8%)</p></td></tr></tbody></table><p>TDF&nbsp;=&nbsp;tenofovir disoproxil</p><p>TAF = tenofovir alafenamide</p><p>a.&nbsp;&nbsp;&nbsp; Week 48 window was between Day 295 and 378 (inclusive).</p><p>b.&nbsp;&nbsp; As determined by the modified US FDA-defined snapshot algorithm.</p><p>c.&nbsp; Open-label phase, Week 96 window is between Day 589 and 840 (inclusive).</p><p>d.&nbsp;&nbsp; No patient discontinued treatment due to lack of efficacy.</p><p>e.&nbsp;&nbsp;&nbsp; Adjusted by baseline age groups (&lt; 50, &ge; 50 years) and baseline HBeAg status strata.</p><p>f.&nbsp;&nbsp;&nbsp; Includes patients who discontinued for reasons other than an AE, death or lack of efficacy, e.g., withdrew consent, loss to follow-up, etc.</p><p><u>&nbsp;</u></p><p><strong>Table&nbsp;8: Additional </strong><strong>Efficacy Parameters </strong><strong>at Week </strong><strong>48 and Week 96<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p><strong>TAF</strong><br /><strong>(N=243)</strong></p></td><td style="vertical-align:bottom"><p><strong>TDF</strong><br /><strong>(</strong><strong>N</strong><strong>=245)</strong></p></td><td style="vertical-align:bottom"><p><strong>TAF-TAF</strong><br /><strong>(N=243)</strong></p></td><td style="vertical-align:bottom"><p><strong>TDF-TAF</strong><br /><strong>(N=245)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Week 48</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Week 96</strong></p></td></tr><tr><td colspan="3"><p><strong>ALT</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td><p>Normal ALT (Central Lab)</p></td><td><p>89%</p></td><td><p>85%</p></td><td style="vertical-align:top"><p>88%</p></td><td style="vertical-align:top"><p>91%</p></td></tr><tr><td><p>Normal ALT (AASLD)</p></td><td><p>79%</p></td><td><p>75%</p></td><td style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>87%</p></td></tr><tr><td><p>Normalized&nbsp;ALT (Central Lab)<sup>b,c,d</sup></p></td><td><p>50%<sup> </sup></p></td><td><p>37%<sup> </sup></p></td><td><p>56%</p></td><td><p>79%</p></td></tr><tr><td><p>Normalized&nbsp;ALT (AASLD)<sup>e,f,g</sup></p></td><td><p>50%</p></td><td><p>26%</p></td><td><p>56%</p></td><td><p>74%</p></td></tr><tr><td colspan="5"><p><strong>Serology</strong></p></td></tr><tr><td><p>HBeAg Loss / Seroconversion<sup>h</sup></p></td><td><p>8% / 3%</p></td><td><p>6% / 0</p></td><td><p>18% / 5%</p></td><td><p>9% / 3%</p></td></tr><tr><td><p>HBsAg Loss / Seroconversion</p></td><td><p>0 / 0</p></td><td><p>2% / 0</p></td><td><p>2% / 1%</p></td><td><p>2% / &lt;&nbsp;1%</p></td></tr></tbody></table><p>TDF&nbsp;=&nbsp;tenofovir disoproxil</p><p>TAF = tenofovir alafenamide</p><p>a.&nbsp;&nbsp;&nbsp; Missing = failure analysis</p><p>b.&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above upper limit of normal (ULN) of the central laboratory range (&gt; 43 U/L males 18 to &lt; 69 years and &gt; 35 U/L males &ge; 69 years; &gt; 34 U/L females 18 to &lt; 69 years and &gt; 32 U/L females &ge; 69 years) at baseline.</p><p>c.&nbsp;&nbsp;&nbsp; Proportion of patients at Week 48: TAF, 16/32; TDF, 7/19.</p><p>d.&nbsp;&nbsp; Proportion of patients at Week 96: TAF, 18/32; TDF, 15/19.</p><p>e.&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the 2018 American Association of the Study of Liver Diseases (AASLD) criteria (35 U/L males and 25 U/L females) at baseline.</p><p>f.&nbsp;&nbsp;&nbsp; Proportion of patients at Week 48: TAF, 26/52; TDF, 14/53.</p><p>g.&nbsp;&nbsp; Proportion of patients at Week 96: TAF, 29/52; TDF, 39/53</p><p>h.&nbsp;&nbsp; The population used for serology analysis included only patients with antigen (HBeAg) positive and anti-body (HBeAb) negative or missing at baseline.</p><p><u>&nbsp;</u></p><p><em>Changes in bone mineral density </em><em>in Study&nbsp;4018</em></p><p>The mean percentage change in BMD from baseline to Week 48 as assessed by DXA was +1.7% with tenofovir alafenamide compared to &minus;0.1% with tenofovir disoproxil at the lumbar spine and +0.7% compared to &minus;0.5% at the total hip. BMD declines of greater than 3% at the lumbar spine were experienced by 4% of tenofovir alafenamide patients and 17% of tenofovir disoproxil patients at Week 48. BMD declines of greater than 3% at the total hip were experienced by 2% of tenofovir alafenamide patients and 12% of tenofovir disoproxil patients at Week 48.</p><p>&nbsp;</p><p>In the open-label phase, mean percentage change in BMD from baseline to Week 96 in patients who remained on tenofovir alafenamide was +2.3% at the lumbar spine and +1.2% at the total hip, compared to +1.7% at the lumbar spine and +0.2% at the total hip in those who switched from tenofovir disoproxil to tenofovir alafenamide at Week 48.</p><p>&nbsp;</p><p><em>Changes in renal laboratory tests in Study 4018</em></p><p>The median change from baseline to Week 48 in eGFR by Cockcroft-Gault method was 2.2 mL per minute in the tenofovir alafenamide group and &minus;1.7 mL per minute in those receiving tenofovir disoproxil. At Week 48, there was a median increase from baseline in serum creatinine among patients randomised to continue treatment with tenofovir disoproxil (0.01&nbsp;mg/dL) compared with a median decrease from baseline among those who were switched to tenofovir alafenamide (0.01 mg/dL).</p><p>In the open-label phase, the median change in eGFR from baseline to Week 96 was 1.6 mL/min in patients who remained on tenofovir alafenamide, compared to +0.5 mL/min in patients who switched from tenofovir disoproxil to tenofovir alafenamide at Week 48. The median change in serum creatinine from baseline to Week 96 was &minus;0.02 mg/dL in those who remained on tenofovir alafenamide, compared to &minus;0.01 mg/dL in those who switched from tenofovir disoproxil to tenofovir alafenamide at Week 48.</p><p><u>&nbsp;</u></p><p><em>Changes in lipid laboratory tests in Study 4018</em></p><p>Changes from double-blind baseline to Week 48 and Week 96 in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio are presented in Table 9.</p><p><u>&nbsp;</u></p><p><strong>Table 9: Median Changes in Lipid Laboratory Tests at Week 48 and Week 96</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>TAF</strong></p><p><strong>(N=236)</strong></p></td><td style="vertical-align:top"><p><strong>TAF</strong></p><p><strong>(N=226)</strong></p></td><td style="vertical-align:top"><p><strong>TAF-TAF</strong></p><p><strong>(N=220)</strong></p></td><td style="vertical-align:top"><p><strong>TDF</strong></p><p><strong>(N=230)</strong></p></td><td style="vertical-align:top"><p><strong>TDF</strong></p><p><strong>(N=222)</strong></p></td><td style="vertical-align:top"><p><strong>TDF-TAF </strong></p><p><strong>N=219)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Baseline</strong></p></td><td style="vertical-align:top"><p><strong>Week 48</strong></p></td><td style="vertical-align:top"><p><strong>Week 96</strong></p></td><td style="vertical-align:top"><p><strong>Baseline</strong></p></td><td style="vertical-align:top"><p><strong>Week 48</strong></p></td><td style="vertical-align:top"><p><strong>Week 96</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>(Q1, Q3) (mg/dL)</p></td><td style="vertical-align:top"><p>Median change<sup>a</sup> (Q1, Q3) (mg/dL)</p></td><td style="vertical-align:top"><p>Median change (Q1, Q3) (mg/dL)</p></td><td style="vertical-align:top"><p>(Q1, Q3) (mg/dL)</p></td><td style="vertical-align:top"><p>Median change<sup>a</sup> (Q1, Q3) (mg/dL)</p></td><td style="vertical-align:top"><p>Median change (Q1, Q3) (mg/dL)</p></td></tr><tr><td style="vertical-align:top"><p>Total Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>166 (147, 189)</p></td><td style="vertical-align:top"><p>19 (6, 33)</p></td><td style="vertical-align:top"><p>16 (3, 30)</p></td><td style="vertical-align:top"><p>169 (147, 188)</p></td><td style="vertical-align:top"><p>&minus;4 (&minus;16, 8)</p></td><td style="vertical-align:top"><p>15 (1, 28)</p></td></tr><tr><td style="vertical-align:top"><p>HDL-Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>48 (41, 56)</p></td><td style="vertical-align:top"><p>3 (&minus;1, 8)</p></td><td style="vertical-align:top"><p>4 (&minus;1, 10)</p></td><td style="vertical-align:top"><p>48 (40, 57)</p></td><td style="vertical-align:top"><p>&minus;1 (&minus;5, 2)</p></td><td style="vertical-align:top"><p>4 (0, 9)</p></td></tr><tr><td style="vertical-align:top"><p>LDL-Cholesterol (fasted)</p></td><td style="vertical-align:top"><p>102 (87,123)</p></td><td style="vertical-align:top"><p>16 (5, 27)</p></td><td style="vertical-align:top"><p>17 (6, 28)</p></td><td style="vertical-align:top"><p>103 (87, 120)</p></td><td style="vertical-align:top"><p>1 (&minus;8, 12)</p></td><td style="vertical-align:top"><p>14 (3, 27)</p></td></tr><tr><td style="vertical-align:top"><p>Triglycerides (fasted)<sup>b</sup></p></td><td style="vertical-align:top"><p>90 (66, 128)</p></td><td style="vertical-align:top"><p>16 (&minus;3, 44)</p></td><td style="vertical-align:top"><p>9 (&minus;8, 28)</p></td><td style="vertical-align:top"><p>89 (68, 126)</p></td><td style="vertical-align:top"><p>&minus;2 (&minus;22, 18)</p></td><td style="vertical-align:top"><p>8 (&minus;8, 38)</p></td></tr><tr><td style="vertical-align:top"><p>Total Cholesterol to HDL ratio</p></td><td style="vertical-align:top"><p>3.4 (2.9, 4.2)</p></td><td style="vertical-align:top"><p>0.2 (&minus;0.1, 0.5)</p></td><td style="vertical-align:top"><p>0.0 (&minus;0.3, 0.3)</p></td><td style="vertical-align:top"><p>3.4 (2.9, 4.2)</p></td><td style="vertical-align:top"><p>0.0 (&minus;0.3, 0.3)</p></td><td style="vertical-align:top"><p>0.0 (&minus;0.3, 0.3)</p></td></tr></tbody></table><p>TDF = tenofovir disoproxil</p><p>TAF = tenofovir alafenamide</p><p>a.&nbsp;&nbsp;&nbsp; P-value was calculated for the difference between the TAF and TDF groups at Week 48, from Wilcoxon Rank Sum test and was statistically significant (p &lt; 0.001) for median changes (Q1, Q3) from baseline in total cholesterol, HDL‑cholesterol, LDL‑cholesterol, triglycerides and total cholesterol to HDL ratio.</p><p>b.&nbsp;&nbsp; Number of patients for triglycerides (fasted) for TAF group was N=235 at baseline, N=225 at Week 48 and N=218 for TAF-TAF group at Week 96.</p><p><u>&nbsp;</u></p><p><em><u>Renal and/or hepatic impairment Study&nbsp;4035</u></em></p><p><em>Study&nbsp;4035</em> was an open-label clinical study to evaluate the efficacy and safety of switching from another antiviral regimen to tenofovir alafenamide in virologically suppressed HBV‑infected patients. Part A of the study included patients with moderate to severe renal impairment (eGFR by Cockcroft-Gault method between 15 and 59&nbsp;mL/min; Cohort 1, N&nbsp;=&nbsp;78) or ESRD (eGFR by Cockcroft-Gault method&nbsp;&lt;&nbsp;15&nbsp;mL/min) on hemodialysis (Cohort 2, N&nbsp;=&nbsp;15). Part B of the study included patients (N&nbsp;=&nbsp;31) with moderate or severe hepatic impairment (Child-Pugh Class B or C at screening or a history of CPT score&nbsp;&ge;&nbsp;7 with any CPT score&nbsp;&le;&nbsp;12 at screening). &nbsp;</p><p>&nbsp;</p><p>The primary endpoint was the proportion of patients with HBV DNA &lt; 20 IU/mL at Week 24. Secondary efficacy endpoints at Weeks 24 and 96 included the proportion of patients with HBV DNA &lt; 20 IU/mL and target detected/not detected (ie, &lt; LLOD), the proportion of patients with biochemical response (normal ALT and normalised ALT), the proportion of patients with serological response (loss of HBsAg and seroconversion to anti-HBs and loss of HBeAg and seroconversion to anti-HBe in HBeAg-positive patients) and change from baseline in CPT and Model for End Stage Liver Disease (MELD) scores for hepatically impaired patients in Part B.</p><p><em>&nbsp;</em></p><p><em>Renally impaired adult patients in Study 4035, Part A </em></p><p>At baseline, 98% (91/93) of patients in Part A had HBV DNA &lt; 20 IU/mL and 66% (61/93) had an undetectable HBV DNA level. Median age was 65 years, 74% were male, 77% were Asian, 16% were White, and 83% were HBeAg-negative. The most commonly used HBV medication oral antivirals included tenofovir disoproxil (N = 58), lamivudine (N = 46), adefovir dipivoxil (N = 46), and entecavir (N&nbsp;= 43). At baseline, 97% and 95% of patients had ALT &le; ULN based on central laboratory criteria and 2018 AASLD criteria, respectively; median eGFR by Cockcroft-Gault was 43.7 mL/min (45.7&nbsp;mL/min in Cohort 1 and 7.32 mL/min in Cohort 2); and 34% of patients had a history of cirrhosis.</p><p>&nbsp;</p><p>Treatment outcomes of <em>Study 4035</em> Part A at Weeks 24 and 96 are presented in Table 10.</p><p>&nbsp;</p><p><strong>Table&nbsp;10: Efficacy Parameters for Renally Impaired Patients at Weeks 24 and 96</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Cohort 1<sup>a</sup></strong></p><p><strong>(N=78)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Cohort 2<sup>b</sup></strong></p><p><strong>(N= 15)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(N=93)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>Week 96</p></td><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>Week 96</p></td><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>Week 96<sup>d</sup></p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>HBV DNA<sup>c</sup></strong><strong> </strong></p></td></tr><tr><td style="vertical-align:top"><p>HBV DNA &lt; 20 IU/mL</p></td><td style="vertical-align:top"><p>76/78 (97.4%)</p></td><td style="vertical-align:top"><p>65/78 (83.3%)</p></td><td style="vertical-align:top"><p>15/15 (100.0%)</p></td><td style="vertical-align:top"><p>13/15 (86.7%)</p></td><td style="vertical-align:top"><p>91/93 (97.8%)</p></td><td style="vertical-align:top"><p>78/93</p><p>(83.9%)</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>ALT<sup>c</sup></strong></p></td></tr><tr><td><p>Normal ALT (Central Lab)</p></td><td style="vertical-align:top"><p>72/78 (92.3%)</p></td><td style="vertical-align:top"><p>64/78 (82.1%)</p></td><td style="vertical-align:top"><p>14/15 (93.3%)</p></td><td style="vertical-align:top"><p>13/15 (86.7%)</p></td><td style="vertical-align:top"><p>86/93 (92.5%)</p></td><td style="vertical-align:top"><p>77/93 (82.8%)</p></td></tr><tr><td><p>Normal ALT (AASLD)<sup>e</sup></p></td><td style="vertical-align:top"><p>68/78 (87.2%)</p></td><td style="vertical-align:top"><p>58/78 (74.4%)</p></td><td style="vertical-align:top"><p>14/15 (93.3%)</p></td><td style="vertical-align:top"><p>13/15 (86.7%)</p></td><td style="vertical-align:top"><p>82/93 (88.2%)</p></td><td style="vertical-align:top"><p>71/93 (76.3%)</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part A Cohort 1 includes patients with moderate or severe renal impairment</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Part A Cohort 2 includes patients with ESRD on hemodialysis</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Missing = Failure analysis</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; The denominator includes 12 patients (11 for Cohort 1 and 1 for Cohort 2) who prematurely discontinued study drug.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018 American Association of the Study of Liver Diseases (AASLD) criteria</p><p>&nbsp;</p><p><em>Hepatically impaired adult patients in Study 4035, Part B</em></p><p>At baseline, 100% (31/31) of patients in Part B had baseline HBV DNA &lt; 20 IU/mL and 65% (20/31) had an undetectable HBV DNA level. Median age was 57 years (19% &ge; 65 years), 68% were male, 81% were Asian, 13% were White, and 90% were HBeAg-negative. The most commonly used HBV medication oral antivirals included tenofovir disoproxil (N = 21), lamivudine (N = 14), entecavir (N = 14), and adefovir dipivoxil (N = 10). At baseline, 87% and 68% of patients had ALT &le; ULN based on central laboratory criteria and 2018 AASLD criteria, respectively; median eGFR by Cockcroft-Gault was 98.5&nbsp;mL/min; 97% of patients had a history of cirrhosis, median (range) CPT score was 6 (5&minus;10), and median (range) MELD score was 10 (6&minus;17).</p><p>&nbsp;</p><p>Treatment outcomes of <em>Study 4035</em> Part B at Weeks 24 and 96 are presented in Table 11.</p><p><strong>Table&nbsp;11: Efficacy Parameters for Hepatically Impaired Patients at Weeks 24 and 96</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Part B</strong></p><p><strong>(N=31)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Week 24</p></td><td style="vertical-align:top"><p>Week 96<sup>b</sup></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>HBV DNA<sup>a</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>HBV DNA &lt; 20 IU/mL</p></td><td style="vertical-align:top"><p>31/31 (100.0%)</p></td><td style="vertical-align:top"><p>24/31 (77.4%)</p></td></tr><tr><td colspan="3"><p><strong>ALT<sup>a</sup></strong></p></td></tr><tr><td><p>Normal ALT (Central Lab)</p></td><td style="vertical-align:top"><p>26/31 (83.9%)</p></td><td style="vertical-align:top"><p>22/31 (71.0%)</p></td></tr><tr><td><p>Normal ALT (AASLD)<sup>c</sup></p></td><td style="vertical-align:top"><p>25/31 (80.6%)</p></td><td style="vertical-align:top"><p>18/31 (58.1%)</p></td></tr><tr><td colspan="3"><p><strong>CPT and MELD Score</strong></p></td></tr><tr><td><p>Mean change from Baseline in CPT Score (SD)</p></td><td style="vertical-align:top"><p>0 (1.1)</p></td><td style="vertical-align:top"><p>0 (1.2)</p></td></tr><tr><td><p>Mean change from Baseline in MELD Score (SD)</p></td><td style="vertical-align:top"><p>-0.6 (1.94)</p></td><td style="vertical-align:top"><p>-1.0 (1.61)</p></td></tr></tbody></table><p>CPT = Child-Pugh Turcotte;</p><p>MELD = Model for End-Stage Liver Disease</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Missing = Failure analysis</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; The denominator includes 6 patients who prematurely discontinued study drug</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2018 American Association of the Study of Liver Diseases (AASLD) criteria</p><p><em>&nbsp;</em></p><p><em>Changes in lipid laboratory tests in Study 4035</em></p><p>Small median increases from baseline to Week 24 and Week 96 in total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio among patients with renal or hepatic impairment are consistent when compared with results observed from other studies involving switch to tenofovir alafenamide (see section 5.1 for <em>Studies 108, 110 and 4018</em>), whereas decreases from baseline in total cholesterol, LDL-cholesterol, triglycerides, and total cholesterol to HDL ratio were observed in patients with ESRD on haemodialysis at Week 24 and Week 96.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>In <em>Study 1092</em>, the efficacy and safety of tenofovir alafenamide were evaluated in a randomised, double‑blind, placebo-controlled clinical study of treatment‑na&iuml;ve and treatment-experienced HBV‑infected patients between the ages of 12 to &lt;&nbsp;18 years weighing &ge;&nbsp;35&nbsp;kg (Cohort 1; N=47 tenofovir alafenamide, N=23 placebo), and 6 to &lt;&nbsp;12 years weighing &ge;&nbsp;25&nbsp;kg (Cohort 2 Group 1; N=12 tenofovir alafenamide, N=6 placebo). Patients were randomised to receive tenofovir alafenamide or placebo to match once daily. Baseline demographics and HBV disease characteristics were comparable between the two treatment arms; 58% were male, 66% were Asian, and 25% were White; 7%, 23%, 24%, and 44% had HBV genotype A, B, C, and D, respectively. Overall, 99% were HBeAg positive. At baseline, median HBV DNA was 8.1&nbsp;log<sub>10</sub>&nbsp;IU/mL, mean ALT was 107&nbsp;U/L, median HBsAg was 4.5&nbsp;log<sub>10</sub>&nbsp;IU/mL. Previous treatment included oral antivirals (23%), including entecavir (N=10), lamivudine (N=12), and tenofovir disoproxil (N=3), and/or interferons (15%). After receiving double-blind treatment for 24 weeks (either tenofovir alafenamide or placebo), patients rolled over with no interruption in treatment to open-label tenofovir alafenamide.</p><p>&nbsp;</p><p>The primary efficacy endpoint was the proportion of patients with plasma HBV DNA &lt;&nbsp;20&nbsp;IU/mL at Week 24. Additional efficacy endpoints included change from baseline in HBV DNA and ALT, ALT normalisation, HBeAg loss and seroconversion, and HBsAg loss and seroconversion.</p><p>&nbsp;</p><p>Treatment outcomes of <em>Study 1092</em> at Week 24 and Week 48 are presented in Table 12 and Table 13.</p><p><strong>Table&nbsp;12: Efficacy Parameters for Paediatric Patients at Week 24</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>TAF</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Cohort 1</strong></p><p><strong>(N=47)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2 Group 1 </strong></p><p><strong>(N=12)</strong></p></td><td style="vertical-align:top"><p><strong>Total </strong></p><p><strong>(N=59)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort&nbsp;1</strong></p><p><strong>(N=23)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2 Group 1 </strong></p><p><strong>(N=6)</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(N=29) </strong></p></td></tr><tr><td colspan="7"><p><strong>HBV DNA</strong></p></td></tr><tr><td style="vertical-align:top"><p>HBV DNA &lt; 20 IU/mL<sup>a</sup></p></td><td style="vertical-align:top"><p>10/47 (21%)</p></td><td style="vertical-align:top"><p>1/12 (8%)</p></td><td style="vertical-align:top"><p>11/59 (19%)</p></td><td style="vertical-align:top"><p>0/23 (0%)</p></td><td style="vertical-align:top"><p>0/6 (0%)</p></td><td style="vertical-align:top"><p>0/29 (0%)</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD) change from baseline in HBV DNA (log<sub>10</sub> IU/mL)</p></td><td style="vertical-align:top"><p>‑5.04 (1.544)</p></td><td style="vertical-align:top"><p>‑4.76 (1.466)</p></td><td style="vertical-align:top"><p>‑4.98 (1.520)</p></td><td style="vertical-align:top"><p>‑0.13 (0.689)</p></td><td style="vertical-align:top"><p>0.00 (0.346)</p></td><td style="vertical-align:top"><p>‑0.10 (0.636)</p></td></tr><tr><td colspan="7"><p><strong>ALT</strong></p></td></tr><tr><td><p>Median (Q1, Q3) change from baseline in ALT (U/L)</p></td><td style="vertical-align:top"><p>‑32.0 (‑63.0, ‑13.0)</p></td><td style="vertical-align:top"><p>‑29.0 (‑81.0, ‑5.5)</p></td><td style="vertical-align:top"><p>‑32.0 (‑65.0, ‑7.0)</p></td><td style="vertical-align:top"><p>1.0 (‑10.0, 25.0)</p></td><td style="vertical-align:top"><p>‑12.0 (‑22.0, ‑2.0)</p></td><td style="vertical-align:top"><p>‑2.5 (‑15.0, 22.0)</p></td></tr><tr><td><p>Normalised ALT (Central Lab)<sup>a,b</sup></p></td><td style="vertical-align:top"><p>28/42 (67%)</p></td><td style="vertical-align:top"><p>7/10 (70%)</p></td><td style="vertical-align:top"><p>35/52 (67%)</p></td><td style="vertical-align:top"><p>1/21 (5%)</p></td><td style="vertical-align:top"><p>0/6</p></td><td style="vertical-align:top"><p>1/27 (4%)</p></td></tr><tr><td><p>Normalised ALT (AASLD)<sup>a,c,d</sup></p></td><td style="vertical-align:top"><p>20/46 (44%)</p></td><td style="vertical-align:top"><p>5/10 (50%)</p></td><td style="vertical-align:top"><p>25/56</p><p>(45%)</p></td><td style="vertical-align:top"><p>0/22</p></td><td style="vertical-align:top"><p>0/6</p></td><td style="vertical-align:top"><p>0/28 (0%)</p></td></tr><tr><td colspan="7"><p><strong>Serology<sup>e</sup></strong></p></td></tr><tr><td><p>HBeAg Loss and Seroconversion<sup>a,f</sup></p></td><td style="vertical-align:top"><p>3/46 (7%)</p></td><td style="vertical-align:top"><p>1/12 (8%)</p></td><td style="vertical-align:top"><p>4/58 (7%)</p></td><td style="vertical-align:top"><p>1/23 (4%)</p></td><td style="vertical-align:top"><p>0/6 (0%)</p></td><td style="vertical-align:top"><p>1/29 (3%)</p></td></tr></tbody></table><p>TAF = tenofovir alafenamide</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Missing = Failure analysis</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the central laboratory range at baseline. Central laboratory ULN for ALT are as follows: 34 U/L for females aged 2 or older or males aged 1‑9 years old and 43 U/L for males aged older than 9 years.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the AASLD criteria (30 U/L for males and females based on the range for paediatric participants) at baseline.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; American Association of the Study of Liver Diseases (AASLD) criteria.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No patient in either group had HBsAg loss or seroconversion at Week 24.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The population used for serology analysis included only patients with antigen (HBeAg) positive and antibody (HBeAb) negative or missing at baseline.</p><p>&nbsp;</p><p><strong>Table&nbsp;13: Efficacy Parameters for Paediatric Patients at Week 48</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>TAF</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo roll over to TAF</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Cohort 1</strong></p><p><strong>(N=47)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2 Group 1 </strong></p><p><strong>(N=12)</strong></p></td><td style="vertical-align:top"><p><strong>Total </strong></p><p><strong>(N=59)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort&nbsp;1</strong></p><p><strong>(N=23)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2 Group 1 </strong></p><p><strong>(N=6)</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(N=29) </strong></p></td></tr><tr><td colspan="7"><p><strong>HBV DNA</strong></p></td></tr><tr><td style="vertical-align:top"><p>HBV DNA &lt; 20 IU/mL<sup>a</sup></p></td><td style="vertical-align:top"><p>19/47 (40%)</p></td><td style="vertical-align:top"><p>3/12 (25%)</p></td><td style="vertical-align:top"><p>22/59 (37%)</p></td><td style="vertical-align:top"><p>5/23 (22%)</p></td><td style="vertical-align:top"><p>1/6 (17%)</p></td><td style="vertical-align:top"><p>6/29 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD) change from baseline in HBV DNA (log<sub>10</sub> IU/mL)</p></td><td style="vertical-align:top"><p>‑5.65 (1.779)</p></td><td style="vertical-align:top"><p>‑5.88 (0.861)</p></td><td style="vertical-align:top"><p>‑5.70 (1.626)</p></td><td style="vertical-align:top"><p>‑5.06 (1.703)</p></td><td style="vertical-align:top"><p>-4.16 (2.445)</p></td><td style="vertical-align:top"><p>‑4.88 (1.867)</p></td></tr><tr><td colspan="7"><p><strong>ALT</strong></p></td></tr><tr><td><p>Median (Q1, Q3) change from baseline in ALT (U/L)</p></td><td style="vertical-align:top"><p>‑38.0 (‑70.0, ‑12.0)</p></td><td style="vertical-align:top"><p>‑30.0 (‑82.0, ‑2.5)</p></td><td style="vertical-align:top"><p>‑37.0 (‑70.0, ‑8.0)</p></td><td style="vertical-align:top"><p>-26.0 (‑55.0, ‑9.0)</p></td><td style="vertical-align:top"><p>‑30.5 (‑53.0, ‑12.0)</p></td><td style="vertical-align:top"><p>‑26 (‑54.0, ‑12.0)</p></td></tr><tr><td><p>Normalised ALT (Central Lab)<sup>a,b</sup></p></td><td style="vertical-align:top"><p>33/42 (79%)</p></td><td style="vertical-align:top"><p>7/10 (70%)</p></td><td style="vertical-align:top"><p>40/52 (77%)</p></td><td style="vertical-align:top"><p>13/21 (62%)</p></td><td style="vertical-align:top"><p>4/6 (67%)</p></td><td style="vertical-align:top"><p>17/27 (63%)</p></td></tr><tr><td><p>Normalised ALT (AASLD)<sup>a,c,d</sup></p></td><td style="vertical-align:top"><p>25/46 (54%)</p></td><td style="vertical-align:top"><p>5/10 (50%)</p></td><td style="vertical-align:top"><p>30/56</p><p>(54%)</p></td><td style="vertical-align:top"><p>9/22 (41%)</p></td><td style="vertical-align:top"><p>2/6 (33%)</p></td><td style="vertical-align:top"><p>11/28 (39%)</p></td></tr><tr><td colspan="7"><p><strong>Serology<sup>e</sup></strong></p></td></tr><tr><td><p>HBeAg Loss and Seroconversion<sup>a,f</sup></p></td><td style="vertical-align:top"><p>7/46 (15%)</p></td><td style="vertical-align:top"><p>3/12 (25%)</p></td><td style="vertical-align:top"><p>10/58 (17%)</p></td><td style="vertical-align:top"><p>2/23 (9%)</p></td><td style="vertical-align:top"><p>0/6 (0%)</p></td><td style="vertical-align:top"><p>2/29 (7%)</p></td></tr></tbody></table><p>TAF = tenofovir alafenamide</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Missing = Failure analysis</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the central laboratory range at baseline. Central laboratory ULN for ALT are as follows: 34 U/L for females aged 2 or older or males aged 1‑9 years old and 43 U/L for males aged older than 9 years.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The population used for analysis of ALT normalisation included only patients with ALT above ULN of the AASLD criteria (30 U/L for males and females based on the range for paediatric participants) at baseline.</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp; American Association of the Study of Liver Diseases (AASLD) criteria.</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No patient in either group had HBsAg loss or seroconversion at Week 48.</p><p>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The population used for serology analysis included only patients with antigen (HBeAg) positive and antibody (HBeAb) negative or missing at baseline.</p><p>&nbsp;</p><p><em>Changes in bone mineral density in Study 1092</em></p><p>Among the patients treated with tenofovir alafenamide and placebo, the mean percent increase in BMD from baseline to Week 24 was +1.6% (N=48) and +1.9% (N=23) for lumbar spine, and +1.9% (N=50) and +2.0% (N=23) for whole body, respectively. At Week 24, mean changes from baseline BMD Z-scores were +0.01 and -0.07 for lumbar spine, and -0.04 and -0.04 for whole body, for the tenofovir alafenamide and placebo groups, respectively.</p><p>&nbsp;</p><p>In the open-label phase, mean percentage increase in BMD from baseline to Week 48 for lumbar spine and whole body was +3.8% (N=52) and +3.0% (N=54) in patients who remained on tenofovir alafenamide, compared to +2.8% (N=27) and +3.7% (N=27) in those who switched from placebo to tenofovir alafenamide at Week 24, respectively. At Week 48, mean changes from baseline BMD‑Z&nbsp;scores for lumbar spine and whole body were -0.05 and ‑0.15 for patients who remained on tenofovir alafenamide, compared to -0.12 and ‑0.07 for those who switched to tenofovir alafenamide, respectively.</p><p>&nbsp;</p><p>BMD declines of 4% or greater at lumbar spine and whole body at Week 24 and Week 48 are presented in Table 14.</p><p>&nbsp;</p><p><strong>Table&nbsp;14: Bone Mineral Density Decreases of 4% or Greater for Paediatric Patients at Weeks 24 and 48 (Whole Body/Lumbar Spine DXA Analysis Set)</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>TAF</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Placebo roll over to TAF at Week 24</strong></p></td></tr><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Cohort 1</strong></p><p><strong>(N=44<sup>a</sup>)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2 Group 1 </strong></p><p><strong>(N=12)</strong></p></td><td style="vertical-align:top"><p><strong>Total </strong></p><p><strong>(N=56)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort&nbsp;1</strong></p><p><strong>(N=21)</strong></p></td><td style="vertical-align:top"><p><strong>Cohort 2 Group 1 </strong></p><p><strong>(N=6)</strong></p></td><td style="vertical-align:top"><p><strong>Total</strong></p><p><strong>(N=27) </strong></p></td></tr><tr><td colspan="7"><p><strong>Week 24</strong></p></td></tr><tr><td style="vertical-align:top"><p>Whole body at least 4% decrease<sup>b</sup></p></td><td style="vertical-align:top"><p>0/39</p></td><td style="vertical-align:top"><p>1/11 (9.1%)</p></td><td style="vertical-align:top"><p>1/50 (2.0%)</p></td><td style="vertical-align:top"><p>0/18</p></td><td style="vertical-align:top"><p>0/5</p></td><td style="vertical-align:top"><p>0/23</p></td></tr><tr><td style="vertical-align:top"><p>Lumbar spine at least 4% decrease<sup>c</sup></p></td><td style="vertical-align:top"><p>0/37</p></td><td style="vertical-align:top"><p>3/11 (27.3%)</p></td><td style="vertical-align:top"><p>3/48 (6.3%)</p></td><td style="vertical-align:top"><p>0/18</p></td><td style="vertical-align:top"><p>0/5</p></td><td style="vertical-align:top"><p>0/23</p></td></tr><tr><td colspan="7"><p><strong>Week 48</strong></p></td></tr><tr><td><p>Whole body at least 4% decrease<sup>b</sup></p></td><td style="vertical-align:top"><p>1/42 (2.4%)</p></td><td style="vertical-align:top"><p>0/12</p></td><td style="vertical-align:top"><p>1/54 (1.9%)</p></td><td style="vertical-align:top"><p>1/21 (4.8%)</p></td><td style="vertical-align:top"><p>0/6</p></td><td style="vertical-align:top"><p>1/27 (3.7%)</p></td></tr><tr><td><p>Lumbar spine at least 4% decrease<sup>c</sup></p></td><td style="vertical-align:top"><p>0/40</p></td><td style="vertical-align:top"><p>2/12 (16.7%)</p></td><td style="vertical-align:top"><p>2/52 (3.8%)</p></td><td style="vertical-align:top"><p>0/21</p></td><td style="vertical-align:top"><p>1/6 (16.7%)</p></td><td style="vertical-align:top"><p>1/27 (3.7%)</p></td></tr></tbody></table><p>TAF = tenofovir alafenamide</p><p>Denominator is the number of patients with nonmissing postbaseline values.</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N=42 for Lumbar Spine DXA Analysis Set in Cohort 1 TAF</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Only patients with nonmissing whole body bone mineral density at baseline were included in the Whole Body DXA Analysis Set.</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Only patients with nonmissing lumbar spine bone mineral density at baseline were included in the Lumbar Spine DXA Analysis Set.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Following oral administration of tenofovir alafenamide under fasted conditions in adult patients with chronic hepatitis&nbsp;B, peak plasma concentrations of tenofovir alafenamide were observed approximately 0.48&nbsp;hours post‑dose.&nbsp; Based on Phase&nbsp;3 population pharmacokinetic analysis in patients with chronic hepatitis&nbsp;B, mean steady state AUC<sub>0‑24</sub> for tenofovir alafenamide (N&nbsp;=&nbsp;698) and tenofovir (N&nbsp;=&nbsp;856) were 0.22&nbsp;&micro;g&bull;h/mL and 0.32&nbsp;&micro;g&bull;h/mL, respectively. Steady state C<sub>max</sub> for tenofovir alafenamide and tenofovir were 0.18 and 0.02&nbsp;&micro;g/mL, respectively. Relative to fasting conditions, the administration of a single dose of tenofovir alafenamide with a high fat meal resulted in a 65%&nbsp;increase in tenofovir alafenamide exposure.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p>&nbsp;</p><p>The binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%. The binding of tenofovir to human plasma proteins is less than 0.7% and is independent of concentration over the range of 0.01‑25&nbsp;&micro;g/mL.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for &gt;&nbsp;80% of an oral dose. <em>In&nbsp;vitro</em> studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by carboxylesterase‑1 in hepatocytes; and by cathepsin&nbsp;A in peripheral blood mononuclear cells (PBMCs) and macrophages. <em>In&nbsp;vivo</em>, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite, tenofovir diphosphate.</p><p>&nbsp;</p><p><em>In&nbsp;vitro</em>, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Tenofovir alafenamide is minimally metabolised by CYP3A4.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p>&nbsp;</p><p>Renal excretion of intact tenofovir alafenamide is a minor pathway with &lt;&nbsp;1% of the dose eliminated in urine. Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir. Tenofovir alafenamide and tenofovir have a median plasma half‑life of 0.51 and 32.37&nbsp;hours, respectively.&nbsp; Tenofovir is renally eliminated from the body by the kidneys by both glomerular filtration and active tubular secretion.</p><p><u>&nbsp;</u></p><p><u>Linearity/non‑linearity</u></p><p>&nbsp;</p><p>Tenofovir alafenamide exposures are dose proportional over the dose range of 8 to 125&nbsp;mg.</p><p>&nbsp;</p><p><u>Pharmacokinetics in special populations</u></p><p><em>&nbsp;</em></p><p><em>Age, gender and ethnicity</em></p><p>No clinically relevant differences in pharmacokinetics according to age or ethnicity have been identified. Differences in pharmacokinetics according to gender were not considered to be clinically relevant.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in patientswith normal hepatic function. When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No clinically relevant differences in tenofovir alafenamide or tenofovir pharmacokinetics were observed between healthy patientsand patients with severe renal impairment (estimated CrCl &gt;&nbsp;15 but &lt;&nbsp;30&nbsp;mL/min) in studies of tenofovir alafenamide (Table&nbsp;15).</p><p>&nbsp;</p><p>Exposures of tenofovir in patientswith ESRD (estimated creatinine clearance&nbsp;&lt;&nbsp;15&nbsp;mL/min) on chronic haemodialysis who received tenofovir alafenamide (N&nbsp;=&nbsp;5) were substantially higher than in subjects with normal renal function (Table&nbsp;15).&nbsp; No clinically relevant differences in tenofovir alafenamide pharmacokinetics were observed in patients with ESRD on chronic haemodialysis as compared to those with normal renal function.</p><p>&nbsp;</p><p><strong>Table&nbsp;15: </strong><strong>Pharmacokinetics of Tenofovir Alafenamide and its Metabolite Tenofovir in Patients with Renal Impairment as Compared to Patients with Normal Renal Function</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>AUC<sub> </sub>(mcg</strong>&bull;<strong>hour per mL)</strong></p><p><strong>Mean (CV%)</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Estimated Creatinine Clearance<sup>a</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>Normal renal function</strong></p><p><strong>&ge;&nbsp;90&nbsp;mL per minute</strong></p><p><strong>(N&nbsp;=&nbsp;13)<sup>b</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>Severe renal impairment</strong></p><p><strong>15&ndash;29&nbsp;mL per minute</strong></p><p><strong>(N&nbsp;=&nbsp;14)<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>ESRD on haemodialysis</p><p>&lt;&nbsp;15&nbsp;mL per minute</p><p>(N&nbsp;=&nbsp;5)<sup>c</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Tenofovir alafenamide</p></td><td><p>0.27 (49.2)<sup>d</sup></p></td><td><p>0.51 (47.3)<sup>d</sup></p></td><td><p>0.30 (26.7)<sup>e</sup></p></td></tr><tr><td style="vertical-align:bottom"><p>Tenofovir</p></td><td><p>0.34 (27.2)<sup>d</sup></p></td><td><p>2.07 (47.1)<sup>d</sup></p></td><td><p>18.8 (30.4)<sup>f</sup></p></td></tr></tbody></table><p>CV = coefficient of variation</p><p>a.&nbsp;&nbsp;&nbsp; By Cockcroft-Gault method.</p><p>b.&nbsp;&nbsp; PK assessed on a single dose of tenofovir alafenamide 25&nbsp;mg in patients with normal renal function and in patients with severe renal impairment in Study GS-US-120-0108.</p><p>c.&nbsp;&nbsp;&nbsp; PK assessed prior to haemodialysis following multiple-dose administration of tenofovir alafenamide 25&nbsp;mg in 5&nbsp;HBV-infected patients in Study GS-US-320-4035.&nbsp; These patients had a median baseline eGFR by Cockcroft-Gault of 7.2&nbsp;mL/min (range, 4.8 to 12.0).</p><p>d.&nbsp;&nbsp; AUC<sub>inf</sub>.</p><p>e.&nbsp;&nbsp;&nbsp; AUC<sub>last</sub>.</p><p>f.&nbsp;&nbsp;&nbsp; AUC<sub>tau</sub>.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Steady-state pharmacokinetics of tenofovir alafenamide and its metabolite tenofovir were evaluated in HBV-infected paediatric patients 12 to &lt;&nbsp;18 years weighing &ge;&nbsp;35 kg and 6 to &lt;&nbsp;12 years weighing &ge;&nbsp;25 kg (Table 16).</p><p>&nbsp;</p><p><strong>Table&nbsp;16: Pharmacokinetics of Tenofovir Alafenamide and its Metabolite Tenofovir in Paediatric Patients Aged 6 to &lt;&nbsp;18 Years and Adults</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>Parameter Mean (CV%)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6 to &lt; 12 years old weighing &ge; 25 kg<sup>a</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>12 to &lt; 18 years old weighing &ge; 35 kg<sup>a</sup></strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Adults<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>TAF</strong></p></td><td style="vertical-align:top"><p><strong>Tenofovir</strong></p></td><td style="vertical-align:top"><p><strong>TAF</strong></p></td><td style="vertical-align:top"><p><strong>Tenofovir</strong></p></td><td style="vertical-align:top"><p><strong>TAF</strong></p></td><td style="vertical-align:top"><p><strong>Tenofovir</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>max</sub> (&micro;g/mL)</strong></p></td><td><p>0.185 (77.7)</p></td><td><p>0.017 (19.7)</p></td><td><p>0.169 (80.9)</p></td><td><p>0.015 (27.4)</p></td><td><p>0.178 (53.4)</p></td><td><p>0.017 (35.2)</p></td></tr><tr><td style="vertical-align:top"><p><strong>AUC<sub>tau</sub> (&micro;g&bull;h/mL)</strong></p></td><td><p>0.206 (61.3)</p></td><td><p>0.298 (23.1)</p></td><td><p>0.215 (91.3)</p></td><td><p>0.251 (23.6)</p></td><td><p>0.216 (66.6)</p></td><td><p>0.322 (31.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>C<sub>trough</sub> (&micro;g/mL)</strong></p></td><td><p>NA</p></td><td><p>0.010 (29.5)</p></td><td><p>NA</p></td><td><p>0.009 (25.6)</p></td><td><p>NA</p></td><td><p>0.011 (33.0)</p></td></tr></tbody></table><p>CV = coefficient of variation; TAF= tenofovir alafenamide; NA = not applicable</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Population PK-derived parameters from <em>Study 1092</em> (6 to &lt;&nbsp;12 years old weighing &ge;&nbsp;25 kg, N=12; 12 to &lt;&nbsp;18 years old weighing &ge;&nbsp;35 kg, N=47).</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Population PK-derived parameters from <em>Studies 108 and 110 </em>(TAF:<em> </em>N=698, Tenofovir: N=856).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical studies in rats and dogs revealed bone and kidney as the primary target organs of toxicity. &nbsp;Bone toxicity was observed as reduced BMD in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of tenofovir alafenamide. A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17&nbsp;times greater, respectively, than those expected after administration of tenofovir alafenamide.</p><p>&nbsp;</p><p>Tenofovir alafenamide was not mutagenic or clastogenic in conventional genotoxic assays.</p><p>&nbsp;</p><p>Because there is a lower tenofovir exposure in rats and mice after tenofovir alafenamide administration compared to tenofovir disoproxil, carcinogenicity studies and a rat peri‑postnatal study were conducted only with tenofovir disoproxil. No special hazard for humans was revealed in conventional studies of carcinogenic potential with tenofovir disoproxil (as fumarate) and toxicity to reproduction and development with tenofovir disoproxil (as fumarate) or tenofovir alafenamide. &nbsp;Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. &nbsp;However, tenofovir disoproxil reduced the viability index and weight of pups in a peri‑postnatal toxicity study at maternally toxic doses. A long‑term oral carcinogenicity study in mice showed a low incidence of duodenal tumours, considered likely related to high local concentrations in the gastrointestinal tract at the high dose of 600&nbsp;mg/kg/day. The mechanism of tumour formation in mice and potential relevance for humans is uncertain.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>&nbsp;</p><p>Lactose monohydrate</p><p>Microcrystalline cellulose (E460(i))</p><p>Croscarmellose sodium (E468)</p><p>Magnesium stearate (E470b)</p><p>&nbsp;</p><p><u>Film‑coating</u></p><p>&nbsp;</p><p>Polyvinyl alcohol (E1203)</p><p>Titanium dioxide (E171)</p><p>Macrogol (E1521)</p><p>Talc (E553b)</p><p>Iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture. Keep the bottle tightly closed. Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High density polyethylene (HDPE) bottles, enclosed with a polypropylene continuous‑thread, child‑resistant cap, lined with an induction‑activated aluminium foil liner. Each bottle contains silica&nbsp;gel desiccant and polyester coil.</p><p>&nbsp;</p><p>The following pack size is available: outer cartons containing 1&nbsp;bottle of 30&nbsp;film‑coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
Tel: +353 (0) 21 483 5500
Fax: +353 (0) 21 483 5518
Email: csafety@gilead.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2023
	
EUMAY23SANOV24

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>